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Arthritis is the most common cause of chronic pain in older people.  Pain is a 
priority for patients and an important clinical symptom, as it predicts service 
use, disability and joint replacements.  Treatment options remain palliative, 
and effect sizes suboptimal.  This thesis investigates correlates, determinants 
and modifiers of musculoskeletal pain. 
The first study utilised data from TASOAC, a population of community 
dwelling older adults aged 50–80 randomly selected from the electoral roll 
and followed for five years to describe associations between aspects of 
osteoarthritis (OA) and quality of life.  This study identified that pain at all joint 
sites is common in older adults, is stable over time, and is the strongest 
musculoskeletal correlate of quality of life. Pain also mediates the association 
between diagnosed OA and quality of life. 
In the second study, in this same population, associations between serum 
vitamin D (25–OHD) and change in knee and hip pain were investigated.  
Moderate (but not mild) vitamin D deficiency independently predicted incident 
or worsening in knee pain over 5 years and possibly hip pain over 2.4 years.  
Therefore correcting moderate vitamin deficiency may attenuate worsening of 
knee or hip pain in elderly persons but supplementing people with a higher 
25–OHD level is unlikely to be effective. 
In the third and fourth studies, potential modifiers of musculoskeletal pain 
were investigated.  In the former, efficacy of thrice daily topical 4Jointz 
utilizing Acteev technology (a combination of a standardized comfrey extract 
and pharmaceutical grade tannic acid, 3.5 g/day) vs placebo was assessed 




clinically defined knee OA, pain on most days, and VAS pain intensity 
≥40mm (n=133).  Topical treatment using 4Jointz reduced pain compared to 
placebo (VAS -9.9 mm, p=0.034; KOOS pain scale +5.7, p = 0.047), but had 
no effect on inflammation or cartilage breakdown over 12 weeks of treatment. 
In the fourth study, efficacy of zoledronic acid (ZA: 5mg/100ml) vs placebo 
over 12 months in participants aged ≥50 years with clinically defined knee 
OA, pain on most days, VAS pain intensity ≥40mm and a bone marrow lesion 
visible on T2-weighted MR images (n=59) was assessed.  Treatment with ZA 
(compared to placebo) improved VAS pain scores after six months (-14.5 
mm, p=0.04) but not after three or twelve months.  ZA treatment reduced 
total BML area compared to placebo after six months (-175.7 mm2, p=0.024); 
with a trend after twelve months (-146.5 mm2, p=0.095).  This provided the 
first evidence of a treatment to modify structural progression in OA. 
In conclusion, this series of studies indicate that pain is a strong and stable 
musculoskeletal correlate of quality of life over time, vitamin D is a 
determinant of musculoskeletal pain, and treatment with 4Jointz and ZA are 
both effective in reducing pain.  Additionally, ZA modifies structural 
progression by reducing total BML area; therefore, a lesion–specific 
approach to treatment of osteoarthritis pain is feasible.  Future work should 
include targeting cognitive correlates of pain, clinical trials of vitamin D 
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Note:  Abbreviations appearing only in summary tables of treatment 
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Chapter 1. Introduction to the determinants, 
correlates and modifiers of musculoskeletal pain 
1.1 The importance and prevalence of pain 
Pain, the “unpleasant sensation associated with actual or potential tissue 
damage...” (Dirckx, 1997), is a familiar human experience.  It is an important 
clinical symptom, and a priority for patients (Heiberg and Kvien, 2002).  
Musculoskeletal pain predicts numerous clinically relevant outcomes, 
including service use (Dominick, 2004), disability (Croft, 2005) and joint 
replacements (Gossec, 2005; Hawker, 2006; Conaghan, 2010; Jüni, 2003).  
Two important characteristics of pain are its frequency and intensity.  The 
exact prevalence of pain in any particular group depends upon the definition 
used (Pereira, 2011) and the time reference.  Overall prevalence of 
musculoskeletal pain in community–dwelling adults appears to be 
approximately 45–66% (Picavet and Schouten, 2003; Thomas, 2004; Zhai, 
2006), and the prevalence of pain at most sites increases with advancing 
age (Picavet and Schouten, 2003; Urwin, 1998), and is higher in 
women (Picavet and Schouten, 2003; Zhai, 2006; Keenan, 2006). 
Knees are either the most common (Keenan, 2006; Thomas, 2004) or one of 
the most common sites of joint pain in older people (Picavet and Schouten, 
2003).  Pain of the hip or knee are also the sites in which the greatest age-
related increases in prevalence occurred (Picavet and Schouten, 2003).  
Joint pain typically affects multiple joints (Picavet and Schouten, 2003; 
Keenan, 2006; Thomas, 2004; Dawson, 2004).   
 




The most common cause of chronic pain in older people is arthritis (Peat, 
2001; Britt, 2010), from the Greek arthron (joint) and –itis meaning 
(inflammation)), thereby being a (painful) disease characterised by 
inflammation of a joint or joints (Dirckx, 1997) 
1.2.1 Disease burden and economic impact 
Based on self–reports, estimates from the 2007–08 National Health Survey 
found that more than 6.3 million Australians (31%) have arthritis or some 
other musculoskeletal condition.  The most common type of arthritis is 
osteoarthritis (OA), affecting 1.6 million Australians (8% of the population), 
followed by rheumatoid arthritis, which is estimated to affect 429,000 
Australians (2%).  (Australia’s Health 2010 (AIHW, 2010)).  OA 
predominantly affects the large joints.   
Of the 561,300 respondents to the National Health Survey who listed arthritis 
or a related disorder as their main health condition, 30% rated limitations in 
their core activities as severe or profound (ABS, 2003), showing that arthritis 
can be extremely disabling.Arthritis and musculoskeletal conditions 
constituted the fourth largest component of direct health expenditure in 
2004–05, at 7.5% of allocated health expenditure or AUD$4.0 billion (AIHW, 
2009), after cardiovascular diseases ($5.9 billion), oral health ($5.3 billion) 
and mental disorders ($4.1 billion).  Osteoarthritis costs are dominated by 
admitted patient services, mostly related to knee and hip joint 
replacements (AIHW, 2009), whereas in persons with rheumatoid arthritis, 
around half of the direct costs were for prescription pharmaceuticals.  Actual 
expenditure on arthritis and musculoskeletal conditions increased from the 
2000–01 to 2004–05 estimates, increasing annually by around 5.2% (after 
adjusting for inflation and excluding research expenditure).  Increases in 
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expenditure are predicted to continue by an estimated 223% between 2002–
03 and 2032–33 (Goss, 2008).  Ageing, increases in the volume of 
treatment(s) per case, and growing population are cited as the factors driving 
these cost increases.  Therefore, arthritis is common, disabling and 
expensive.  The burden of musculoskeletal disorders on the community has 
been recognised on both national and international levels, with the Australian 
Government declaring arthritis and musculoskeletal conditions as a national 
health priority area in 2002, and at an international level with 2000–2010 
declared the Bone and Joint Decade.   
1.2.2 General definitions of osteoarthritis 
OA was once described as a degenerative, or “wear and tear” disease, but 
this is now considered incorrect (Creamer and Hochberg, 1997; Loeser, 
2012).  Osteoarthritis is now defined as a “progressive disease of synovial 
joints that represents failed repair of joint damage that results from stresses 
that may be initiated by an abnormality in any of the synovial joint tissues…. 
this ultimately results in the breakdown of cartilage and bone, leading to 
symptoms of pain, stiffness and functional disability” (Lane, 2011).   
Therefore, osteoarthritis is a disease of the whole joint, and although its 
signature pathologic features are articular cartilage loss and damage of 
adjacent bone (Arden and Nevitt, 2006), it commonly involves many other 
joint structures including subchondral bone, ligaments, menisci, periarticular 
muscles, peripheral nerves, and synovium (Lane, 2011; Loeser, 2012).  The 
failure of these joint tissues results in a common outcome – pain and reduced 
function (Creamer and Hochberg, 1997), but involve no common pathological 
pathway (Lane, 2011).  Therefore, there must be a range of determinants of 
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disease, with different entities as potential therapeutic targets, not all of which 
will benefit the entire patient population with osteoarthritis.  
1.3 The nexus of pain and osteoarthritis: Radiographic vs. 
clinical definitions of osteoarthritis 
Osteoarthritis has historically been defined in two ways: firstly, using features 
visible on radiographs without reference to pain.  Examples include the 
classic grading system of Kellgren and Lawrence (Kellgren and Lawrence, 
1957) (see Table 1.1), or the more recent OARSI grading system (Altman, 
1995), for grading osteoarthritis according to individual features visible on 
radiographs (from 0–3, where 0=absent and 3=severe), rather than the joint 
as a whole.  Some advantages of using these radiographic classifications are 
that they are objective, can be standardised, and the technology is well–
established, but disadvantages include the lack of correlation to the most 
important concern of patients (pain) (Heiberg and Kvien, 2002), the inability 
to visualise non-calcified tissues, their two–dimensional nature, measurement 
error and semi-quantitative assessment (Jones, 2004).  
Table 1.1. Radiographic criteria for assessment of osteoarthritis using the 
Kellgren and Lawrence (KL) grading system 
Definition grades Description 
Grade 0: No osteoarthritis No features of osteoarthritis  
Grade 1: Doubtful Minute osteophyte, doubtful significance 
Grade 2: Mild Definite osteophytes, unimpaired joint space 
Grade 3: Moderate Moderate diminution of joint space 
Grade 4: Severe Joint space greatly impaired with sclerosis of 
subchondral bone 
From Arden and Nevitt, 2006; based on Kellgren and Lawrence, 1957. 
 
Secondly, OA can be defined clinically, such as the American College of 
Rheumatology (ACR) definition which does include pain, specifically “pain for 
most days of the month”, in addition to other clinical features (Altman, 1986).  
These definitions are most useful for epidemiological and clinical studies 
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rather than clinical practice, as the initial criteria were designed to 
differentiate patients with OA from those with rheumatoid arthritis (McAlindon 
and Dieppe, 1989).   
The relative importance of pain versus radiographic or imaging findings in 
osteoarthritis is the subject of some debate (Cibere, 2006; LaValley, 2001).  
Radiologic features are poor predictors of clinical outcomes, certainly in knee 
osteoarthritis (Bruyere, 2002).  Radiographic markers of osteoarthritis are 
only weakly associated with pain (Bedson and Croft, 2008; Hannan, 2000; 
Michel, 1997; Dahaghin, 2005), with only 15–53% of persons with knee pain 
having prevalent radiographic OA using a global assessment scale, such as 
the Kellgren–Lawrence system (Cibere, 2006).  Results of a systematic 
review and literature search investigating putative discordance between 
clinical and radiographic knee osteoarthritis (Bedson and Croft, 2008) 
concluded that reported discordance exists due to the nature and extent of 
radiographic views (for example, patellofemoral joint views are often omitted), 
how symptoms are defined, and the nature of the study group (Bedson and 
Croft, 2008).  When authors have attempted to control for potential reasons 
for discordance, observed discordance reduces (Duncan, 2007).  However, 
lack of concordance does not equate to lack of aetiologic association.  This 
apparent discordance may simply reflect that there are many other factors 
that cause pain other than structures that appear on radiographs. 
Newer imaging modalities such as MRI allow visualisation of other structures 
which have been associated with pain (Felson, 2001; Speer, 1992; Koo, 
1999; Zhang, 2011), and a study from our centre showed that radiographic 
features of knee OA (osteophytes, knee JSN) were not associated with 
prevalent knee pain after adjustment for other structural factors (Zhai, 2006).  
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Therefore, it is clear that that investigation into correlates, determinants and 
modifiers of musculoskeletal pain must look beyond radiographs.  
1.4 Pain 
1.4.1 Correlates of pain 
Numerous studies have investigated correlates of pain, including 
demographic and social factors as well as associations between features of 
OA visible on radiographs and MR imaging.  Correlates at several sites are 
discussed in detail as follows.   
1.4.1.1 Knee 
Non-psychological correlates of knee pain have been well reviewed in Jones 
et al, 2011 (Jones, 2011).  Obesity, weak muscles, and numerous structures 
have been independently associated with pain.  These structures include 
bone marrow lesions, cartilage defects, meniscal tears (posterior horn), 
osteophytes (but not independently of MRI changes), joint effusions, and 
synovitis.  Tibial bone size, subchondral bone mass, meniscal extrusion and 
cartilage volume are not associated with pain, and associations between 
anterior cruciate ligament tears and knee pain are controversial (Jones, 
2011).  In our cohort, both prevalent knee pain and more severe knee pain is 
associated with: increasing body mass index (BMI), reduced knee extension 
strength, bone marrow lesions (BMLs), full–thickness and non–full–thickness 
chondral defects of the medial tibial compartment, and hip (but not knee) joint 
space narrowing (JSN), but not osteophytes (Zhai, 2006).   
1.4.1.2 Hip  
Less attention has been directed to pain at other sites.  With regards to pain 
in the hip, only a few authors investigated multiple correlates of hip 
pain (Hopman-Rock, 1996; Juhakoski, 2008; Summers, 1988; Thumboo, 
2002; van Baar, 1998), with only one of these studies solely investigating 
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persons with hip pain (Juhakoski, 2008) rather than a mixed population of 
people with knee and hip pain. 
Associations have been observed between number of comorbidities, duration 
of concomitant knee pain, and life satisfaction, but not BMI, radiologic score 
of hip OA, leg extensor strength or depression (as measured by the Beck 
Depression Inventory (Juhakoski, 2008).  BMI was associated with WOMAC 
function scores, but not WOMAC pain (Juhakoski, 2008).   
Regarding radiographic features of hip OA, synovitis, and possibly labrum hip 
BMLs have been associated with hip pain cross–sectionally, after adjustment 
for age, sex and BMI (Roemer, 2011).  In another cross–sectional study, 
BML size was found to be related to the magnitude of hip pain (Taljanovic, 
2008).  Indeed, prevalence of BMLs and synovitis was 100% in a sample of 
patients with severe hip pain and rapidly progressing radiologic features of 
hip OA (Boutry, 2002).  
1.4.1.3 Low back  
Cross–sectional correlates of low back pain include previous back injury, 
physical and mental stress at work (Heliovaara, 1991), social 
deprivation (Croft and Rigby, 1994; Webb, 2003) and pain at other 
sites (Heliovaara, 1991; Webb, 2003).  Correlations between low back pain 
and clinical findings on physical examination are poor (Michel, 1997).  A 
systematic review of cohort studies found that psychological factors (notably 
distress, depressive mood, and somatization) are implicated in the transition 
from acute to chronic low back pain (Pincus, 2002).  Conflicting findings on 
the association between obesity and smoking with low back pain are 
discussed later (see section 1.4.1.5: “Correlates across sites” on page 43).  
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Presence of vertebral endplate signal changes visible on MR imaging (Modic 
changes) (de Roos, 1987; Modic, 1988) have been consistently associated 
with low back pain symptoms, with a systematic review reporting significant 
associations between Modic changes and low back pain (OR’s from 2.0 to 
19.9) (Jensen, 2008).  Patients with persistent Type 1 Modic changes have 
poor prognosis over a follow up period of 14 months (Jensen, 2012), but 
unlike knee BMLs, there is no association between the change in size of type 
1 Modic changes and change in low back pain intensity (OR 1.0) (Jensen, 
2012). 
1.4.1.4 Hand  
Dahaghin and colleages (Dahaghin, 2005) investigated correlates of hand 
pain, finding that pain in the neck and shoulder, OA of any joint, female sex, 
and presence of rheumatoid arthritis or a thyroid disorder were all associated 
with hand pain in a multivariate model; but that diabetes, obesity, previous 
fracture of the wrist or hand, or having a manual occupation were not.  The 
evidence for an association between radiographic OA and hand function 
impairment is inconsistent, ranging from no association to a moderate 
association (Dahaghin, 2006).  Assessment of features using ultrasound 
imaging, which showed that while persons with painful joints are more likely 
to demonstrate ultrasound–detected pathology, the extent or total amount of 
pathology observed did not correlate with symptoms (Keen, 2008), but the 
sample size was small.  Using MR imaging, synovitis, BMLs, erosions and 
attrition have been associated with joint tenderness (Haugen, 2012).  
Therefore, if pathological features are associated with pain, it appears more 
likely that it will be the features visible on ultrasound and MR imaging rather 
than those visible only on radiographs which are associated with pain. 
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1.4.1.5 Correlates across sites 
Consistent correlates of pain across sites include psychological factors, poor 
muscle strength, some OA features visible on MR imaging (eg BMLs, 
synovitis), and pain in other joints.  Features visible only on radiographs (eg 
joint space narrowing) are consistently shown to be poorly correlated with 
pain.  Psychological factors are discussed in more detail in section 1.4.3 
(page 47).  Overall, many studies only investigate a few factors in cross–
sectional studies, whereas longitudinal studies are required to assess 
changes over time. 
BMI has been consistently associated with knee pain (Zhai, 2006; Felson, 
2000) and low back pain (Leboeuf-Yde, 2000), but the lack of association in 
the only study of multiple correlates of hip pain (Juhakoski, 2008) suggests 
that at least some correlates of pain may differ by site of pain, a theory 
supported by other authors (Adamson, 2006; Janke, 2007).  Adamson 
(2006)  (65)  (65)  (65) reported cross–sectional associations between 
obesity and pain in the lower limbs but not in the upper limbs, after 
adjustment for sex, cigarette smoking, alcohol consumption and socio–
economic class.  A review of 65 studies investigating obesity and low back 
pain found that while obesity was weakly associated with low back pain, 
results were inconsistent (Leboeuf-Yde, 2000).  However, these studies have 
used weight, BMI and waist–hip ratio, which do not provide information about 
specific components of body composition and therefore no clues as to 
possible mechanisms of action.  A recent cross–sectional study investigated 
the effect of different aspects of excess weight which may explain these 
discrepancies.  In multivariate analysis, they found that BMI was associated 
with low back pain, as was total fat mass and lower limb fat mass (and 
possibly upper limb fat mass), independent of lean mass, but that lean mass 
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was not associated with pain independent of fat mass (Urquhart, 2011).  This 
suggests that the relationship between obesity and low back pain intensity 
includes spinal loading as well as metabolic factors. 
Adamson (2006)  (65)  (65)  (65) also reported associations between 
cigarette smoking and pain in the upper limbs after adjustment for sex, 
alcohol consumption and socio–economic class.  This reached statistical 
significance for back and shoulder pain, but not at other sites (Adamson, 
2006).  There has been significant debate about the role of cigarette smoking 
as a correlate or cause of pain and OA, particularly in the light of a recent 
study (a longitudinal observational study following up a cohort who had taken 
part in an earlier randomised controlled trial).  This demonstrated a strong 
inverse dose–response relationship between duration of smoking and risk of 
lower limb total joint replacement (Mnatzaganian, 2011).  This is in contrast 
to data from other observational studies, which show that the protective effect 
of smoking in OA is likely to be false and related to selection bias in the 
control populations of case–control studies, as it was observed only in 
hospital–based case–control studies (Hui, 2011; Gill and Hill, 2012). Indeed, 
our data suggest smoking is detrimental for spinal OA  (Jones, 1998), and 
cartilage loss in the knee (Ding, 2008) in cross–sectional studies. 
  




1.4.2 Pathogenesis of pain 
The pathogenesis of pain is complex and multifactorial, involving local 
nociception, inflammatory mediators, and central sensitisation. 
Normal cartilage is aneural, but abnormal cartilage is not, with evidence of 
substance P nociceptive fibres in osteoarthritic cartilage (Fortier and Nixon, 
1997; Wojtys, 1990), suggesting that these fibres are involved in the 
signalling and maintenance of pain associated with OA.  Other work has 
demonstrated that prostaglandins are differently regulated in normal and OA-
affected chondrocytes, with up–regulation of cyclooxygenase-2 (COX-2) in 
cartilage specimens from persons with OA, leading to a 50 fold increase in 
prostaglandin E2 (Amin, 1997), which then stimulates bone 
resorption (Robinson, 1975).  This all suggests that abnormal cartilage has a 
direct role as a source of pain. There is increasing interest in the subchondral 
bone in the pathogenesis of OA, and therefore it is interesting and relevant 
that substance P nocioceptive fibres have also been found in the 
subchondral bone (Wojtys, 1990). 
Inflammatory processes are implicated in the pathogenesis of 
musculoskeletal pain.  Inflammation can be localised (eg synovitis) or 
systemic, as indicated by changes in inflammatory markers such as IL–6.  
Biopsies of patients with both early and late knee OA have shown low-grade 
chronic synovitis with production of pro–inflammatory cytokines (Smith, 2003; 
Benito, 2005).  Synovitis has been associated with fluctuations in pain (Hill, 
2007; Zhang, 2011), and interventions aimed at the synovium are effective in 
treating knee pain, such as intra-articular injections of local 
anaesthetic (Creamer, 1996), and corticosteroids 
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 (Dieppe, 1980; Ostergaard, 1996; Raynauld, 2003).  Since other evidence 
suggests that the synovium is richly innervated (Kidd, 1996), overall, this data 
suggests that there is an intra–articular component to knee pain, and that this 
is likely to be due to inflammatory factors. 
The consistent association between presence of BMLs and knee 
pain (Felson, 2001; Felson, 2007; Zhang, 2011; Zhai, 2006), and Carbone’s 
observations that BMLs were significantly less common in users of 
alendronate and oestrogen (Carbone, 2004) suggest that bisphosphonates 
and BMLs (and indeed the subchondral bone as a whole) may provide 
insights in the pathogenesis of pain as well as potential treatments (see 
Chapter 1.5.3 for further exploration of this second theme).  BML–related 
pain could be osteoclast–mediated, since this is one mechanism of action of 
nitrogen-containing bisphosphonates (Rogers, 2003), and a known 
mechanism of bone pain in cancer (Honore and Mantyh, 2000), which is 
often treated with bisphosphonates.   
Bisphosphonates may work through a variety of mechanisms, including 
effects on the subchondral bone and osteochondral junction.  Abnormal bone 
turnover in OA leads to a zone of osteoporosis beneath the thickened 
subchondral plate, altered flexibility, and increased microfracture (Buckland-
Wright, 2007). Osteoclasts mediate the extension of channels from marrow 
spaces into the non-calcified articular cartilage.  The resulting loss of 
osteochondral integrity exposes subchondral nerves to pro–inflammatory and 
algesic factors from the synovial fluid and permits sensory nerve growth into 
the non–calcified articular cartilage (Walsh, 2010). Furthermore, osteoclasts 
may reduce pH at the osteochondral junction, thereby sensitizing and 
activating sensory nerves through actions on ion channels on their peripheral 
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terminals (Yoneda, 2011).  Bisphosphonates are also reported to have anti-
inflammatory actions (Roelofs, 2010; Baroja-Mazo and Pelegrin, 2012); such 
effects may play a role in an immediate analgesic benefit, as distinct from 
that which might arise as a consequence of osteochondral structural 
alteration. Overall, it is clear that the pathogenesis of joint pain is complex 
and multifactorial, involving local nociception, inflammatory mediators, and 
central sensitisation (Dieppe and Lohmander, 2005; Kidd, 1996; Schaible 
and Grubb, 1993), but also that a lesion-specific approach is feasible in 
treating joint pain.  
1.4.3 Other determinants of pain 
The pain experienced by an individual is strongly influenced by 
genetics (Foulkes and Wood, 2008), including genes for thermal pain 
sensitivity.  For example, analyses completed by UK colleagues in 
collaboration with our group used pooled data from 7 cohorts (including 
TASOAC) demonstrated that persons having the TRPV1 585 Ile–Ile 
genotype (associated with lowered peripheral pain sensitivity) were at 
decreased risk of knee OA being painful (OR 0.74) (Valdes, 2011).  This 
further demonstrates that factors other than radiographic changes influence 
pain.  
Vitamin D has also been implicated in the pathogenesis of knee pain, as 
vitamin D deficiency is common in persons with widespread bone and muscle 
pain (McBeth, 2010; Plotnikoff and Quigley, 2003; Block, 2004; Al Faraj and 
Al Mutairi, 2003; Nellen, 1996; Serhan, 1999), although this could be reverse 
causality through the effects of ill health on sunlight exposure and physical 
activity.  The active metabolite 1,25(OH)2D has an antiproliferative effect and 
down-regulates inflammatory markers (Lips, 2006).  We have demonstrated 
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in a smaller sample of our cohort that inflammatory markers are associated 
with change in non-weight bearing knee pain (Stannus, 2013).  Other authors 
have shown that low levels of 25–OHD predicted increased experimental 
pain sensitivity (Glover, 2012), suggesting that vitamin D level may be related 
to pain pathways involved in initial perception of pain.  
Cognitive, psychological, and psychosocial aspects also influence 
pain (Keefe and Somers, 2010; Creamer, 1999), with depressed persons 
experiencing more rapid worsening in knee pain than non–depressed 
persons (Riddle, 2011).  Causality also occurs in the opposite direction; 
osteoarthritic knee or hip pain were determinants of subsequent depressed 
mood through its effect on fatigue and disability (Hawker, 2011).   
Pain catastrophisation has been extensively investigated.  It refers to the 
tendency to focus on and magnify pain sensations, and to feel helpless in the 
face of pain (Sullivan, 2001).  It explains a higher proportion of variance in 
pain cross–sectionally than demographic and medical status variables 
combined (Somers, 2009) and mediates the gender–pain relationship even 
after controlling for depression (Keefe, 2000).  Catastrophisation is related to 
pain severity, pain–related disability, poor outcomes of pain treatment, and 
possibly inflammatory disease activity (Edwards, 2006).   
  




1.5 Treatment options for modifying musculoskeletal pain 
There are a number of treatment options for modifying musculoskeletal pain. 
Guidelines for the use of these therapies for OA of the knee and hip have 
been developed by the relevant professional society (OARSI)  (Zhang, 2008).  
Optimal management of the symptoms of hip and knee OA include a 
combination of non–pharmacological and pharmacological 
modalities (Zhang, 2008), with provision of information about the disease 
process and lifestyle modification, physical activity, weight loss and 
appropriate referral to health professionals eg physiotherapist.  The initial oral 
analgesic for pain relief is paracetamol (<4g/day) followed by non–steroidal 
anti–inflammatory drugs, COX–2 selective agents or non–selective NSAIDs 
co–prescribed with proton–pump inhibitors for prevention of gastro–intestinal 
side effects.  If pain persists, other available therapies include capsaicin, 
injections of corticosteroids, glucosamine sulphate, chondroitin sulphate, and 
weak opioids.  Patients who continue to have inadequate pain relief and 
functional improvement may consider joint replacement surgery (Zhang, 
2008).   
1.5.1 Evidence for efficacy of pain treatments 
Evidence summaries have now been developed for treatment of 
musculoskeletal pain, within the context of knee and hip OA (Zhang, 2010).  
Table 1.2 has been reprinted from Osteoarthritis Cartilage, Vol 18, Zhang W  
et al. OARSI recommendations for the management of hip and knee 
osteoarthritis: part III: Changes in evidence following systematic cumulative 
update of research published through January 2009, pg 476-99, Copyright 
(2010), with permission from Elsevier.  Effect sizes (ES) are standard mean 
difference (i.e., the mean difference between a treatment and a control group 
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divided by the standard deviation of the difference), and are presented for 
function and stiffness. References to original papers have been omitted. 
 
 
Table 1.2: Best evidence for treatment efficacy for pain outcomes, from 
various modalities of therapy for hip and knee OA available 31 January 2009 
(from Zhang, 2010) 
Modality Joint  QoS 
(%) 




Non-pharmacological      
Self-management  Both  100 Ia 0.06 (0.02, 0.10)  
Telephone Both  100 Ia 0.12 (0.00, 0.24)  
Education Both  100 Ia 0.06 (0.03, 0.10)  
Strengthening Knee 100 Ia 0.32 (0.23, 0.42)  
 Hip 100 Ia 0.38 (0.08, 0.68)  
Aerobic Knee 100 Ia 0.52 (0.34, 0.70)  
Water-based exercise Both 100 Ia 0.19 (0.04, 0.35)  
Balneotherapy Knee 75 Ia  NS 
Spa/sauna Both 75 Ib 0.46 (0.17, 0.75) NS 
Weight reduction Knee 100 Ia 0.20 (0.00, 0.39) 3 (2, 9) 
TENS Both 75 Ia  2 (1, 5) 
Laser Both 100 Ia  4 (2,17) 
Ultrasound Both 50 Ia 0.06 (-0.39, 0.52)  
Radiotherapy Both 50 IIb Similar effects between 
OA and RA from an 
MA of uncontrolled trial 
 
Heat/ice Knee 75 Ia 0.69 (-0.07, 1.45)  
Massage Knee 40 Ib 0.10 (-0.23, 0.43)  
Acupuncture Knee 100 Ia 0.35 (0.15, 0.55) 4 (3, 9) 
Insoles Knee 100 Ia No different between 






Knee 100 Ia More benefits with a 
knee brace than a 
neoprene sleeve 
 
Electrotherapy/EMG Knee 100 Ia 0.16 (-0.08, 0.39)  
(Table continues on the next page) 
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Table 1.2 Best evidence for treatment efficacy for pain outcomes (cont.) 
Modality Joint  QoS 
(%) 




Pharmacological      
Acetaminophen Both 100 Ia 0.14 (0.05, 0.23) 3 (2, 52) 
NSAIDs Both 100 Ia 0.29 (0.22, 0.35)  
Cox-2 inhibitors Both 100 Ia 0.44 (0.33, 0.55)  
Topical NSAIDs Knee 100 Ia 0.44 (0.27, 0.62)  
Topical capsaicin Knee 75 Ia  4 (3, 5) 
Opioids Any 100 Ia 0.78 (0.59, 0.98)  
IA corticosteroid Knee 100 Ia 0.58 (0.34, 0.75) 5 (3, 38) 
IAHA Knee 100 Ia 0.60 (0.37, 0.83) 7 (3, 119) 
Glucosamine sulphate Both 100 Ia 0.58 (0.30, 0.87) 5 (4, 7) 
Glucosamine 
hydrochloride 
Knee – Ib -0.02 (-0.15, 0.11  
Chondroitin sulphate Knee 100 Ia 0.75 (0.50, 1.01) 5 (4, 7) 
Diacerhein Both – Ib 0.24 (0.08, 0.39)  
ASU Both 100 Ia 0.38 (0.01, 0.76) 6 (4, 21) 
Rosehip Both 100 Ia 0.37 (0.13, 0.60) 6 (4, 13) 
SAM-e Knee 100 Ia 0.22 (-0.25, 0.69)  
Surgical      
Lavage/debridement Knee – Ib 0.21 (-0.12, 0.54)  
Patellar resurfacing Knee 100 Ib  9 (5, 25) 
Osteotomy Knee 100 Ia Head to head comparisons, no 
placebo or conservative therapy 
controlled trials. HTO improves pain 
and Similar function improvement as 
TKR or HTO, but less complications 
and revision than HTO 
Unicompartment knee 
arthroplasty 
Knee 75 SR 
cohort 
Similar function improvement as TKR 
or HTO, but less complications and 
revision than HTO 
TJR Both 100 III TJR is effective to improve QoL, more 
beneficial for hip OA from an SR of 
cohort studies 
Abbreviations: ASU: avocado soybean unsponifiables; EMG: electromyography 
HTO: high tibial osteotomy; IA: intra–articular; IAHA: intra–articular hyaluronic acid; 
LoE: level of evidence; SAM-e: S-adenosylmethionine; SR: systematic review; 
TENS: trans cutaneous electrical nerve stimulation; TKR: total knee replacement; 
NNT: number needed to treat; NS: not significant; TJR: total joint replacement. 
Ia: Meta–analysis of RCTs; Ib: RCT; IIa controlled study without randomisation; IIb: 
quasi-experimental study (e.g., uncontrolled trial, one arm dose–response trial, etc.); 
III: observational studies (e.g., case–control, cohort, cross-sectional studies); IV: 
expert opinion. 
QoS (highest quality of study) was assessed using validated scales, e.g., the 
Oxman and Guyatt scale for systematic review and the Jadad’s scale for clinical 
trials. The percentage score was calculated for each study. The best available 
evidence was presented, i.e., SR with the highest quality, RCT with highest quality 
followed by uncontrolled or quasi experiment, cohort and case–control study. 
ES = 0.2 is considered small, ES =0.5 is moderate, and ES > 0.8 is large; NNT for 
symptom relief, unless otherwise specified. 
  




These treatments (with the possible exception of glucosamine sulphate and 
chondroitin) are not disease modifying.  Therefore, they provide symptomatic 
relief, but do not change the disease process. 
The most effective of the non–pharmacological therapies are exercise, 
thermal therapies (spa / heat / ice) and acupuncture.  Paracetamol has a very 
small effect size (0.14), while NSAIDs and COX-2 inhibitors have small effect 
sizes (0.29 and 0.44).  Opioids and corticosteroids have large effect sizes 
(0.78 and 0.75), but overall the effect sizes for pain are well below the level of 
pain relief desired by patients.  Therefore, there remains considerable scope 
for additional therapeutic modalities for pain relief from musculoskeletal pain. 
  









1.5.2 Evidence for side effects of pain treatments 
Pharmacological therapies have benefits, but they also have side effects 
associated with their use.  These are summarised in Table 1.3, with 
references in the original text (Zhang, 2010).   
Table 1.3: Side effects associated with pharmacological therapies.  Adapted 
from Zhang, 2010 
Intervention Adverse events RR/OR (95% CI) Evidence 
Acetaminophen  GI discomfort 0.80 (0.27, 2.37) Meta-RCTs 
(paracetamol) GI perforation/bleed 3.60 (2.60, 5.10) CC 
 GI bleeding 1.20 (0.80, 1.70) Meta-CCs 
 GI hospitalisation 1.20 (1.03, 1.40) CS 
 Renal failure 0.83 (0.50, 1.39) CS 
 Renal failure 2.50 (1.70, 3.60) CC 
NSAIDs GI perforation/ulcer/bleed 5.36 (1.79, 16.10) Meta-RCTs 
 GI perforation/ulcer/bleed 2.70 (2.10, 3.50) Meta-CSs 
 GI perforation/ulcer/bleed 3.00 (2.50, 3.70) Meta-CCs 
 GI hospitalisation 1.63 (1.44, 1.85) CS 
 Myocardial infarction 1.09 (1.02, 1.15) Meta-CSs 
Topical NSAIDs GI events 0.81 (0.43, 1.56) Meta-RCTs 
 GI bleed/perforation 1.45 (0.84, 2.50) Case–
control 
 Serious GI complications  0.33 (0.01, 8.14) Meta-RCTs 
 Symptomatic ulcers  0.33 (0.01, 8.14) Meta-RCTs 
 Serious CV or renal 
events  
0.53 (0.08, 3.46) Meta-RCTs 
NSAID +PPI vs  Serious GI complications  0.46 (0.07, 2.92) Meta-RCTs 
NSAID Symptomatic ulcers 0.09 (0.02, 0.47) Meta-RCTs 
 Serious CV or renal 
events  
0.78 (0.10, 6.26) Meta-RCTs 
Cox-2 inhibitors 
+PPI vs Cox-2  
Recurrent ulcer bleeding  8.9% vs 0%   RCT 
inhibitors GI hospitalisation  0.69 (0.52, 0.93) CS 
NSAID  Serous GI complications  0.57 (0.36, 0.91) Meta-RCTs 
+misoprostol Symptomatic ulcers  0.36 (0.20, 0.67) Meta-RCTs 
vs NSAID Serious CV or renal 
events   
1.78 (0.26, 12.07) Meta-RCTs 
 Diarrhoea  1.81 (1.52, 2.61) Meta-RCTs 
(Table continues on the next page) 
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Table 1.3: Side effects associated with pharmacological therapies.  Adapted 
from Zhang, 2010 (cont.) 
Intervention Adverse events RR/OR (95% CI) Evidence 
Cox-2 inhibitors   
   Coxibs vs NSAID Serious GI complications 0.55 (0.38, 0.80) Meta-RCTs 
 Symptomatic ulcers 0.49 (0.38, 0.62) Meta-RCTs 
 Serious CV or renal 
events 
1.19 (0.80, 1.75) Meta-RCTs 
   Celecoxib Myocardial infarction 2.26 (1.00, 5.10) Meta-RCTs 
 Myocardial infarction 0.97 (0.86, 1.08) Meta-
CSs/CCs 
   Rofecoxib Myocardial infarction 2.24 (1.24, 4.02) Meta-RCTs 
 Myocardial infarction 1.27 (1.12, 1.44) Meta-
CSs/CCs 
   Valdecoxib CV events 2.30 (1.10, 4.70) Meta-RCTs 
Opioids Any 1.40 (1.30, 1.60) Meta-RCTs 
 Constipation 4.08 (3.30, 5.05) Meta-RCTs 
 Nausea 3.15 (2.68, 3.72) Meta-RCTs 
 Vomiting 5.99 (4.20, 8.54) Meta-RCTs 
 Dizziness 3.74 (3.00, 4.66) Meta-RCTs 
 Somnolence 4.78 (3.65, 6.26) Meta-RCTs 
Glucosamine Any 0.97 (0.88, 1.08) Meta-RCTs 
Chondroitin sulphate Any 0.99 (0.76, 1.31) Meta-RCTs 
Diacerhein Diarrhoea 3.51 (2.55, 4.83) Meta-RCTs 
IAHA Local adverse events 1.49 (1.21, 1.83) Meta-RCTs 
IA high molecular 
HA (Hylan) 
Flares of pain and swelling 2.04 (1.18, 3.53) Meta-RCTs 
Abbreviations: CC: case–control study; CS: cohort study; PPI: proton pump inhibitor; 
H2-blockers: histamine type 2 receptor antagonists; CV: cardiovascular; IA: intra–
articular. 
 
Table 1.3 has been reprinted from Osteoarthritis Cartilage, Vol 18, Zhang W et al. 
OARSI recommendations for the management of hip and knee osteoarthritis: part III: 
Changes in evidence following systematic cumulative update of research published 
through January 2009, pg 476-99., Copyright (2010), with permission from Elsevier. 
 
Overall, the effects of agents used to treat OA vary, from small to moderate.  
Many of the pharmacological therapies have increased risk of side effects 
associated with their use, and some of the side effects are serious, while 
most of the therapies listed in Table 1.2 are not disease–modifying.  
Therefore there is enormous scope for the development of additional 
effective therapies for OA, especially those which also modify structural 
progression. 
Chapter 1: Introduction to the determinants, correlates and modifiers of musculoskeletal pain 
 
Page 56 
1.5.3 Emerging bone–active treatments for musculoskeletal pain 
New treatments are emerging for musculoskeletal pain using anti–resorptive 
bone agents.  These have been reviewed briefly by Zhang (2010), but the 
field is moving quickly and numerous relevant studies post–date Zhang’s 
review. 
Interest in the field followed Carbone’s (2004) observational study regarding 
the effect of various antiresorptive drugs (oestrogen, raloxifene, and 
alendronate) on structural findings and symptoms of knee OA amongst 
postmenopausal women (Carbone, 2004).  They found that BMLs were 
significantly less common in alendronate users (OR 0.11; p≤0.05) compared 
to women not using any anti–resorptive agents.   
Table 1.4 on page 60 shows experimental studies that investigated the effect 
of a bisphosphonate use on participants with OA and displays pain and 
structural outcomes (other outcomes not shown).  Study quality, site of joint 
pain, duration of follow up and outcomes studied vary; few studies 
specifically investigated the effect of bisphosphonates on structural outcomes 
as well as pain.  There is variation between the effect of different 
bisphosphonates on pain and structure; therefore beneficial effects may be 
limited to some bisphosphonates rather than being a class effect.   
Risedronate is the medication studied in the largest number of patients in 
good quality trials (Table 1.4). Risedronate (15 mg daily) reduced markers of 
cartilage degradation and bone resorption, but differences in pain, 
radiological JSN, JSW or osteophyte formation were not statistically 
significant (Spector, 2005; Bingham, 2006).  Other work demonstrated that 
risedronate 50 mg weekly may prevent an increase in BML size over 24 
months (Raynauld, 2008) although this did not reach statistical significance.  
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Alendronate use had no effect on WOMAC outcomes after six months, and 
this study did not assess any structural outcomes (Jokar, 2010), and 
Fujita (2009) found no difference between the alendronate arm and 
participants receiving calcium alone.  However, there are data suggesting it 
retards spinal osteophyte progression (Neogi, 2008).  Fujita (2009) identified 
beneficial effects of etidronate compared to the calcium only group, but did 
not have any structural endpoints. 
Aside from bisphosphonates, there have been several studies with OA 
endpoints using other medicines with well–described effects in bone, but 
without clear structure modification targets eg BMLs.  There are open–label 
studies, such as one trial for treatment of knee OA with calcitonin (Esenyel, 
2012).  Two double–blind, placebo–controlled RCT’s studies have assessed 
the effect of strontium; one in spine OA (Bruyere, 2008) and one in knee 
OA (Reginster, 2012).  Bruyere (123) (124) (124) demonstrated that 
strontium was effective in improving back pain (using a 5 point Likert scale) 
and reducing disc space narrowing compared to placebo (Bruyere, 2008).  A 
similar trial has been completed in knee OA, demonstrating statistically 
significant reductions in structural and pain endpoints, with reduction in knee 
JSN of 0.10mm (2g/day group), proportion of radiological progressors, 
markers of cartilage breakdown and WOMAC pain scale (3 units) compared 
to placebo over three years.  Observed reductions in VAS of 3.01mm 
(2g/day) did not quite reach statistical significance.  Importantly, this result is 
well below the reductions required for clinically significant reductions of pain 
(15mm), and persistence of patients to the three year endpoint was poor 
(58%) (Reginster, 2012), indicating the difficulty of maintaining patients on 
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treatment regimens over long periods of time, and the possibility of bias in 
the study.   
These agents have all been licensed for use for other indications for some 
time, and the side–effect profiles observed in these studies were consistent 
with those recorded in previous studies (Bruyere, 2008; Reginster, 2012; 
Jokar, 2010; Spector, 2005; Bingham, 2006). 
Therefore, the use of bone–active pharmacological agents for treatment of 
pain in OA and also structural modification is an exciting development in the 
field.   
  






Table 1.4: Experimental studies of bisphosphonates in patients with osteoarthritis, sorted by site and year of publication 
Study Intervention 
and dose 














at 3 months 
Erosive hand OA, 





No 38 24 
months 
VAS p=0.03 







Placebo ACR–defined knee 
OA, daily knee pain, 
aged 40–80 
Knee RCT Yes 284 12 
months 








Placebo ACR–defined knee 
OA, knee pain on 
most days, medio-
tibial mJSW 2–4 
mm, aged 40–80 




















No 142 18 
months 









mg/week, 2 x 
1mg/week 
Hyaluronic 
acid (20mg / 
week) 
ACR–defined knee 










70 mg weekly 
Placebo ACR–defined knee 
OA, WOMAC pain 
score 2/5 & daily 
knee pain for ≥6mo. 





Table continues on next page
  
 
Table 1.4: Experimental studies of bisphosphonates in patients with osteoarthritis, sorted by site and year of publication (cont.) 
Study Intervention 
and dose 












No treatment Back and/or knee 

































for 7 months 
Back or knee pain Knee, 
spine 










Results listed as not significant (ns) if paper does not state p value. 
JSN: joint space narrowing; JSW: joint space width 
§Comparison is for risedronate vs exercise alone 
VRS: Visual rating scale 









Arthritis is the most common cause of chronic pain in older people, affecting 
more than 6.3 million Australians.  The most recent estimates suggest that 
arthritis and musculoskeletal conditions constituted the fourth largest 
component of direct health expenditure, costing the Australian economy 
AUD$4.0 billion annually.  
Correlates of pain are not consistent across all joints, but include obesity, 
weak muscles, pain in other joints and numerous structures visible on MR 
imaging, including bone marrow lesions, cartilage defects, meniscal tears, 
osteophytes (but not independently of MRI changes), joint effusions, and 
synovitis.  Features visible only on radiographs (eg joint space narrowing) are 
poorly correlated with pain.  Cognitive, psychological, and psychosocial 
aspects also influence pain, with causality also working in the opposite 
direction, with evidence that osteoarthritic knee or hip pain determines 
subsequent depressed mood through its effect on fatigue and disability.  
Treatment options for modifying musculoskeletal pain include non–
pharmacological treatments, such as weight loss, physical activity, and 
lifestyle modification.  Pharmaceutical treatments include oral paracetamol, 
NSAIDs, COX–2 inhibitors, glucosamine sulphate, chondroitin sulphate, 
capsaicin, injections of corticosteroids, glucosamine, chondroitin sulphate, 
and weak opioids.  Once conservative measures have failed, surgical 
treatments such as joint replacements may be considered.  The effect of 
treatment from available therapies remains suboptimal, and although existing 
treatments are safe options, all pharmacological and surgical treatments 
have side effects and risks.  There is scope in the current treatment 
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armamentarium for more effective therapies, and even for treatments with 
smaller effect sizes that can be taken in addition to existing medications as 
long as they are safe.  Treatments remain symptom modifying but not truly 
disease modifying.  An agent that achieves symptom modification and 
disease modification remains the “holy grail” for OA treatment. 
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Chapter 2. Research questions 
2.1 Research questions 
Research questions 1 and 2 investigate correlates and one determinant of 
musculoskeletal pain. 
 
In a population-based cohort of community-dwelling adults aged 50–80 years 
examined at baseline and 2.6 and 5 years later: 
1. What is the relationship between osteoarthritis and health–related QoL 
over five years? 
1.1. Is the relationship between these factors the same cross–sectionally 
as it is longitudinally (over 2.6 and five years)? 
1.2. What is the contribution of physician diagnosed OA, radiographic 
measures of knee OA and pain at multiple sites to QoL? 
2. Is there an association between baseline 25-hydroxyvitamin D (25–OHD) 
at baseline, and change in knee pain over 5 years and change in hip pain 
over 2.6 years, as measured by the Western Ontario and McMaster 
University Osteoarthritis Index (WOMAC) questionnaire? 
2.1. If there is an association, what is the nature of that association?  Is 
the association linear or is there a threshold?   
2.2. Is the relationship consistent within WOMAC subscales? 
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Research questions 3 and 4 investigate modifiers of musculoskeletal pain 
using two different treatment modalities in double–blind randomised–
controlled–trials. 
 
3. Is a thrice daily application of topical 4Jointz 3.5 g/day (compared to 
placebo), effective in reducing knee pain, improving muscle strength and 
markers of inflammation and cartilage breakdown over twelve weeks in 
participants aged >50 with OA and a pain intensity score >40mm on a 
visual analogue scale (VAS)? 
3.1.  Does this effect reverse over four weeks after discontinuation of 
4Jointz (compared to placebo)? 
4. Is a single infusion of zoledronic acid 5mg (compared to placebo) 
effective in reducing knee pain and BMLs over twelve months in 
participants aged ≥50 years with ACR–defined clinical knee OA, pain on 
most days and a pain intensity score of >40mm on a visual analogue 
scale (VAS) and a prevalent knee BML? 
4.1. If there is a reduction in areal BML size, is it sufficient to expect that 
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Chapter 3. Methodology 
3.1 Prelude 
Two chapters of this thesis utilise data from the Tasmanian Older Adult 
Cohort (TasOAC) study.  This chapter describes the study design, study 
population, and measurement protocols which are common to these two 
chapters. 
Please note that the following data chapters are presented in the form in 
which they were accepted by, or submitted to peer–reviewed scientific 
journals.  Therefore there are some differences in the way aspects of the 
TASOAC study are described, based on requirements of different journals 
and the emphases required for different analyses.  The sample sizes used in 
individual chapters varies for each of the research questions.  
Chapters 6 and 7 describe the two intervention trials of this thesis – 4Jointz 
and ZAP.  These are both placebo–controlled double–blind randomised 
controlled trials in patients with clinical knee OA.  Study–specific 
methodologies for these two trials appear in these two chapters. 
3.2 TASOAC design and study population  
TASOAC is an ongoing prospective, population–based study which aimed to 
identify the environmental, genetic and biochemical factors associated with 
the development and progression of osteoarthritis (OA) and osteoporosis at 
multiple sites (hand, knee, hip, spine). 
The TASOAC sample consists of men and women aged 50-80 years (mean 
age 62±7 years), selected from the roll of electors in southern Tasmania 
(population 229,000) using stratified simple random sampling without 
replacement.  Stratification was by sex, enabling equal numbers of men and 
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women to be enrolled.  The electoral roll represents the most complete 
population listing of Australian adults available, as voting is compulsory in 
state and federal elections.  As TasOAC was designed to examine 
community–dwelling older adults, institutionalised older adults were excluded 
from the initial sample.  Participants were also excluded if they had contra–
indications for MRI (including pacemakers, implants and claustrophobia), as 
MRI was required to examine OA progression.  Other exclusion criteria 
included body weight exceeding the weight limit on the dual energy X–ray 
absorptiometry (DXA) machine (>135 kg), and inability to come to the clinic 
(for example, if they resided interstate or overseas, see Figure 3.1). 
3.2.1 Ethics 
The Southern Tasmanian Health and Medical Human Research Ethics 
Committee approved the study (Ethics Approval Number: H6488), and we 
obtained written informed consent from all participants.   
3.2.2 Baseline (Phase 1) 
An overview of participant recruitment and withdrawal during the baseline 
phase of TASOAC is shown in Figure 3.1.  2530 people were identified from 
the electoral roll, of which 2135 were identified as initially eligible.  Of the 
people who did not take part in the study, 395 people were identified as not 
being eligible, with the most common reasons being claustrophobia, too sick, 
or living overseas or interstate.  231 people were not able to be contacted, 
804 did not want to enter the study, and one participant failed to attend the 
clinic.  The remaining 1099 people attended the clinic at the Menzies 
Research Institute Tasmania from February 2002 to September 2004.   
The overall response rate for participation in Phase 1 is 57%, which is similar 
to response rates from studies with equivalent response burdens conducted 
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around the same time period, such as the North West Adelaide Health Study 
at 58% (Grant, 2009), and the Australian Diabetes, Obesity and Lifestyle 
Study at 52% (Dunstan, 2002). 
Figure 3.1 provides an overview of participant recruitment into Phase 1.   
Participants in TASOAC completed questionnaires on a wide range of 
demographic factors, as well as a number of specific questionnaires including 
knee pain and stiffness and quality of life.  Participants also attended clinic at 
the Menzies Research Institute Tasmania and supplied a fasting blood 
sample, and had other measures taken in person, such as blood pressure 
and leg strength.  Participants also attended appointments for bone density 
testing (using dual energy X–ray absorptiometry (DXA)), radiography, and 
magnetic resonance imaging). 
  















































Initially Ineligible N=395 
Age ≥ 80 47 
Deceased  31 
Too sick 50 
Living overseas or interstate 53 
Suffered a Stroke 11 
Dementia 19 
Hip/Knee Replacement 39 
>135kgs 11 
Nursing Home 16 
P/maker or implant 15 
Language Problems 15 
Claustrophobia 88 
Total persons identified from 
electoral roll  
n = 2530 





Response rate = 1099/(2135-231)=57% 
Participation rate = 1099/2135=51.5% 
994 participants had baseline MRI 





n = 1099 
Failed to attend clinic n=1 
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Table 3.1 shows that TASOAC participants (n=1099) were representative of 
the 2530 people selected from the electoral roll with regard to sex, (48.9 % 
male vs 50.7% male), and also regard to age for the middle and younger 
third of the cohort (born 1933 – 1945 and 1943 – 1952).  However, the older 
age group (born 1921 – 1933) were under–represented in the 1099 
participants who provided baseline measures (21.4% vs 39.8% and 35.9% 
for the younger groups).   
Table 3.1: Baseline demographic characteristics of those participants who 
completed Phase 1 (n=1099) and those who did not (n=1431)  
 Did not participate 




 n=1431 n=1099 p 
Sex (% Male) 50.7 48.9 0.37 
Age group    
1921-1933 486 (34.0) 235 (21.4) <0.001 
1933-1945 473 (33.1) 437 (39.8)  
1943-1952 423 (29.6) 394 (35.9)  
Age group 1921 - 1933 consists of persons in the age groups "1921-1925" "1923-
1927" "1925-1929" "1928-1932" and "1929-1933". 
Age group "1933 - 1945" consists of persons in the age groups "1933-1937" "1937-
1941" "1938-1942" and "1941-1945". 
Age group "1942 - 1952" consists of persons in the age groups "1943-1947" "1945-
1949" "1948-1952". 
 
3.2.3 2.6 year follow up (Phase 2) 
Participants were contacted and asked to return for subsequent visits after 2–
3 years (mean ± SD 2.6 ± 0.4; range 1.4–4.8 years).  The majority of the 
1099 participants who took part in Phase 1 returned for Phase 2 (80%, see 
Figure 3.2).  As TASOAC aimed to measure osteoarthritis progression, 
participants without baseline MRI were excluded from Phase 2.  The other 
common reasons for patients discontinuing involvement in the study after 
Phase 1 were not wanting to continue in the study.   



































Ineligible   n=162  
 n 
No MRI 84 
Deceased 16 
Moved interstate or overseas 14 
Moved to nursing home 1 
Joint replacement 15 
Physically unable 16 
Other reasons 16 
Refused to continue n=58 
Unable to trace n=4 
Eligible subjects for Phase 2 
n = 1099 
Participation rate = 875/1099=80% 
Phase 2 Participants n=875 
(1099-224 withdrawals) 




TASOAC participants who did not complete Phase 2 were older, more likely 
to be female, shorter and had higher BMI than participants who completed 
both Phase 1 and Phase 2 (Table 3.2). 
Table 3.2: Baseline demographic characteristics of those participants who 
completed Phase 2 (n=875) and those who did not (n=224)  
 Participated in 
Phase 2 
(n=875) 
Did not participate 
in Phase 2 
(n=224) 
p value 
Age (years) 62.7 (7.3) 64.4 (8.2) <0.01 
Male sex (n, %) 445 (51) 92 (41) <0.01 
Height (cm) 167.5 (9.0) 164.9 (8.8) <0.01 
Weight (kg) 77.9 (14.6) 77.7 (16.5) 0.824 
BMI (kg/m2) 27.7 (4.6) 28.5 (5.7) 0.040 
Bolded results indicate statistically significant difference at =0.05 
*Mean (standard deviation) except for percentages. P values determined by t–test or 
chi–square test (where appropriate). BMI: body mass index. 
 
  




3.2.4 Five year follow up (Phase 3) 
Participants who completed Phase 2 were invited to continue participation in 
the study for Phase 3, which occurred 5 years after Phase 1 (mean ± SD   
5.05 ± 0.5; range 3.6 – 6.9 years).   
The most common reasons for patients to discontinue involvement in the 
study after Phase 2 were refusing to continue, physical inability to attend, and 
death (see Figure 3.3).  
 






























Withdrawal reason n=70 n 
No MRI 0 
Deceased 19 
Moved interstate or overseas 12 
Moved to nursing home 6 
Joint replacement 1 
Unable to trace 3 
Physically unable 23 
Willing but unable to attend  3 
Not contacted 2 
Other reasons 1 
Refused to continue 36 
Eligible subjects for Phase 3 
N = 875 
Participation rate = 769/875=87.9% 
Phase 3 Participants N=769 
   (875-106 withdrawals) 
Chapter 3: Methodology 
 
Page 79 
Those completing Phase 3 were younger, taller and had lower BMI at 
baseline than participants who did not complete Phase 3 (Table 3.3).  This 
includes participants who dropped out before Phase 2.   
Table 3.3: Characteristics of study cohort at baseline in participants who did 




Did not participate 
in Phase 3  
 Mean (sd) Mean (sd) p 
 n=769 n=330 value 
Age (years) 62.1 (7.0) 65.2 (8.1) <0.001 
Sex (% male) 49.5 54.8 0.110 
Height 167.5 (8.9) 165.7 (9.2) 0.003 
Weight 77.8 (14.6) 78.1 (15.8) 0.747 
Body mass index 27.7 (4.6) 28.4 (5.1) 0.02 
Bolded results indicate statistically significant difference at =0.05 
*Mean (standard deviation) except for percentages. P values determined by t–test or 
chi–square test (where appropriate). BMI: body mass index. 
  




3.3 Measurement of pain 
Functional MRI (fMRI) is an MRI procedure that measures brain activity by 
detecting associated changes in blood flow.  fMRI scans show altered 
processing of the affective qualities of the ongoing pain (Baliki, 2008; 
Kulkarni, 2007; Parks, 2011), and should give the actual pain patients 
experience (as compared to what they report), as well as answering 
important questions about the nature of pain in patients with osteoarthritis.  
Therefore, this represents the gold standard of pain measurement in an ideal 
world, but fMRI and other brain imaging techniques are limited to specialised 
use and are not currently used as outcome measures in clinical trials or 
epidemiological studies. 
Pain questionnaires and visual analog scales are the usual methods of 
assessing pain intensity due to good reliability, validity, sensitivity to change 
and ease of use, but the potential for under– or over–reporting of pain 
intensity remains.  This may be systematic in nature, and so this limitation 
needs to be considered in data interpretation.   
Questionnaire–based methods of assessing musculoskeletal pain in adults 
can be divided into several categories (Hawker, 2011).  These include: 
 generic unidimensional pain questionnaires (visual analog scale and 
numeric rating scale); 
 generic multidimensional pain questionnaires (Short Form–36 Bodily 
Pain Scale); 
 arthritis–specific pain questionnaires (Measure of Intermittent and 
Constant Osteoarthritis Pain) (Hawker, 2008); and 
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 composite measures of arthritis symptoms, including pain and 
associated disability or dysfunction, such as the Western Ontario and 
the Knee Injury and Osteoarthritis Outcome Score (KOOS) (Roos, 
1998) and McMaster Universities Osteoarthritis Index (Bellamy, 1988).   
In this thesis, we have used visual analog scales, WOMAC and KOOS 
questionnaires to assess pain intensity. 
  




3.4 Study populations 
Participants from TASOAC are utilised in two chapters – Chapter 4 and 
Chapter 5.  A summary of when measures were assessed over all three 
Phases is shown in Table 3.4 on page 89.  This is not an exhaustive list of all 
the measures which were actually taken in TASOAC.  
Chapter 6 and Chapter 7 utilise study participants recruited into the 4Jointz 
and ZAP trials rather than TASOAC.  Characteristics of the study participants 
are presented in each of these chapters.   
Study populations are summarised in Table 3.6 on page 91. 
3.5 Study measures 
Details of how outcome measures and covariates were assessed are 
described below.  Study measures appear here in Chapter 3 if they were 
used in multiple studies or where space restrictions precluded full description 
of methods in published papers.  The location of methods descriptions for 
particular outcomes, predictors or covariates are shown in Table 3.5 on page 
90. 
3.5.1 Anthropometrics 
Body weight was measured to the nearest 0.1 kg (with shoes, socks, and 
bulky clothing removed) using a single pair of electronic scales (Seca Delta 
Model 707, Bradford, MA, USA).  Height was measured to the nearest 0.1 cm 
(with shoes and socks removed) using a stadiometer.  Body mass index 
(BMI) was calculated as weight (kg)/ (height (m))2.  Waist and hip 
circumference were measured to the nearest 0.1 cm using a constant tension 
tape (Figure Finder Tape Measure) directly over the skin.   
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3.5.2 Questionnaire measures 
3.5.3.1 Highest educational attainment 
At baseline, participants were asked “What is the highest qualification you 
have completed?”.  Participants could select one answer only.  Response 
options are as follows:  “No formal qualifications”; “School or Intermediate 
certificate (or equivalent)”; “Higher School or Leaving Certificate (or 
equivalent)”; “Trade/apprenticeship (eg Hairdresser, Chef, Motor Mechanic)”; 
“Certificate/diploma (eg Child Care, Technician, Nursing, Chartered 
Accountant)”; “University Degree”; “Higher University degree”. 
3.5.3.2 Current employment status 
At baseline, participants were asked “Which of the following best describes 
the occupation you had for the longest period?”.  Response options were as 
follows: “Manager or administrator”, “Professional (eg engineer, doctor, 
teacher, nurse, police officer, technical officer)”, “Tradesperson (eg 
carpenter, electrician, plumber, book keeper, etc)”, “Salesperson or personal 
service worker (eg sales rep., teller, insurance rep, real estate rep., etc)”, 
“Plant or machine operator, or driver (eg taxi or bus driver, etc)”, “Clerk (eg 
typist, receptionist, data processor, bookkeeper, etc)”, “farmer”, “Labourer or 
related worker (eg trade assistant, factory hand, agricultural labourer, 
construction, mining)”, “Member of armed forces”, or “other”. 
3.5.3.3 Self–reported arthritis, as diagnosed by a physician 
Participants were asked about presence or absence of physician–diagnosed 
osteoarthritis and pain at baseline at the neck, back, hands, shoulders, hips, 
knees, or feet (yes / no options – see Appendix 1)), and physician–diagnosed 
rheumatoid arthritis (RA) (yes / no). 
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3.5.3.4 Self reported pain 
Similarly, participants were asked whether joint pain was present or absent at 
seven different joints: neck, back, hands, shoulders, hips, knees, or feet (see 
Appendix 1). 
3.5.3.5 Cigarette smoking 
Self–reported estimates of smoking status (never, former, and current) was 
determined by questionnaire from the following questions “Have you ever 
smoked cigarettes on a regular basis?”; “Do you currently smoke 
cigarettes?”, and “If you have given up smoking, at what age did you stop?” 
(see Appendix 1).  Participants were considered a current smoker if they 
reported currently being a “regular smoker”.  
3.5.3.6 Alcohol consumption 
Alcohol consumption was assessed by a validated food frequency 
questionnaire (FFQ) which was developed specifically for use in Australian 
adults (Hodge, 2000).  Participants were asked about their average alcohol 
consumption over the past 12 months. The consumption frequency of each 
alcohol type [beer (low alcohol); beer (full strength); red wine; white wine 
(includes sparkling wines); fortified wines, port, sherry, etc.; and spirits, 
liqueurs, etc.] was asked about separately. An estimated daily intake of 
alcohol (gram/day) was calculated.  
3.5.3.7 Western Ontario McMaster Osteoarthritis Index (WOMAC) 
Self–reported knee and hip pain, function and stiffness were assessed by 
questionnaire for the last 30 days using the Western Ontario McMaster 
Osteoarthritis Index (WOMAC) (Bellamy, 1988) (see Appendix 1).  The 
WOMAC pain scale has five items, each rated on a 10–point scale from 0 (no 
pain) to 9 (most severe pain).  Lower scores indicate lower levels of 
symptoms or physical disability.  Each pain item was summed to create a 
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total pain (0–45) score.  The WOMAC index has good test–retest reliability, 
with values of 0.68 for the pain scale and 0.48 for the function 
scale (Bellamy, 1988), and has demonstrated convergent construct validity 
over numerous impairments (McConnell, 2001).  Responsiveness of the 
WOMAC is variable depending on the intervention measured (McConnell, 
2001), as expected.  
3.5.3 Strength and physical activity measures 
3.5.3.1 Muscle strength 
Leg strength was measured to the nearest kilogram in both legs 
simultaneously, using a dynamometer (TTM Muscular Meter, Tokyo, Japan). 
Participants stood on the back of the dynamometer platform, with back 
straight against a wall and knees flexed to an angle of 115º from the neutral 
angle of full extension (dependent on participant range of motion).  A 
demonstration of the leg strength assessment technique is provided in Figure 
3.4.  A bar connected by a chain to the dynamometer was held on the front of 
the thighs with both hands. Using only their legs and keeping the back and 
neck straight, the participant was then instructed to lift the bar upwards with 
maximum force, and given verbal encouragement until a maximal contraction 
was achieved. This test examines isometric strength of the whole legs, but 
predominantly of the quadriceps and hip extensors.  
Two trials were recorded, with the mean score taken as the criterion value for 
leg strength. A third trial was performed if the score for the first two trials 
varied by more than 10% (Kumar, 2004). Intra–class correlation coefficients 
(ICC’s) demonstrated high reproducibility between trials 1 and 2 at both 
baseline (ICC 0.95, 95% CI 0.94, 0. 96) and follow–up (ICC 0.96, 95% CI 
0.95, 0.97). 




Figure 3.4. Demonstration of the leg strength test performed in the TASOAC 
study (from Scott, 2010). 
 
This measure of muscle strength has not been validated, but quadriceps 
strength as measured by isokinetic knee extension strength tests used in falls 
risk assessment has been previously demonstrated to be a predictor of 
pain, (Zhai, 2006) falls (Lord, 1999), disability (McAlindon, 1993) and 
mortality (Newman, 2006) using similar tests.  Knee extension strength in our 
participants at all points was strongly correlated with leg strength (r = 0.77 at 
Phase 1, r = 0.73 at Phase 2 and r = 0.73 at Phase 3, all p<0.0001) providing 
reassurance about our leg strength measure.  We chose not to include knee 
extension strength in our analyses due to a “ceiling effect” in that 
approximately 20% of participants achieved the maximum reading of 46kg at 
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each of the three time points, and also because it assesses strength over the 
whole leg rather than predominantly the quadriceps. 
3.5.3.2 Pedometers 
Physical activity levels were assessed as steps per day using pedometers 
(Omron HJ–003 and HJ–102; Omron Healthcare, Kyoto, Japan).  
Pedometers were calibrated at the clinic with the participant present, using a 
100–pace walking test.  Participants were shown how to attach the 
pedometers to their waistband or belt and were instructed to wear the 
pedometer above their dominant leg.  Pedometers were calibrated at the 
clinic with the participant present, using a 100–pace walking test.  
Participants were provided with a pedometer diary and were instructed to 
record their steps daily for seven consecutive days from the following day.  
Participants were mailed out a second pedometer after a six month period 
and repeated the process.  A steps per day value was calculated which was 
the daily average of these two time periods.  The start and the finish times of 
pedometer use were recorded on each day, and participants also reported 
the duration and the type of physical activity for any periods in which they did 
not wear the pedometer.  Pedometer readings were excluded if they were 
determined to be caused artificially (eg report of work done on heavy 
machinery), or if the pedometer had been worn for less than five days and for 
less than eight hours on each of these days, excluding reported duration of 
pedometer removal. 
3.5.4 X–ray 
Participants had X–rays of both hips (n=1014) and knees (n=1020) in the 
standing anterio–posterior position at baseline only.  Knee X–rays were taken 
of both knees with 15° of fixed knee flexion, and pelvic radiographs with both 
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feet in 10° internal rotation.  Films were scored individually for osteophytes 
and joint space narrowing (JSN) on a scale of 0–3 (where 0=no disease and 
3=most severe disease) according to the Osteoarthritis Research Society 
International (OARSI) atlas as previously described (Altman, 1995).  This is 
also referred to as “OARSI grade”.  Hips and knees with scores 1–3 at any 
site were classified as having JSN or osteophytes.  Two readers 
simultaneously assessed radiographs with immediate reference to the atlas.  
Scores for each participant were determined by consensus.  Intraobserver 
repeatability was assessed in 40 participants (intraclass correlation 
coefficients (ICCs) 0.65 to 0.85 for the knee and 0.60– 0.87 for the 
hip)  (Foley, 2006).  
  




Table 3.4: Summary of when measures were assessed in the TASOAC study 

















   
WOMAC scale    
  Knee pain 
   
  Hip pain  
  
Pain at any of these sites – neck, back, 
hands, shoulders, hips, knees, feet,  
   
Osteoarthritis diagnosed by a doctor 
(y/n) at neck, back, hands, shoulders, 
hips, knees, feet 
  
 
 Smoking survey  
   
Ever been diagnosed by a doctor (y/n) 
with rheumatoid arthritis 
   
Current medications (dosage, frequency) 
including prescription and over the 
counter medications 
   
Dietary questionnaire (FFQ), including 
alcohol intake 
   
AQOL 
   
Clinic measurements    
Blood taken (vitamin D) 
  
 
Height, weight, girth (hip and waist) 
   
Pedometer (7 days of wear at 2 time 
points 6 months apart) 
   
Leg strength 
   
X-ray    
   Hip 
 
  




MRI    
   Knee 
 (n=425) 
 









3.6 Summary of outcome factors, study factors, and covariates 
Table 3.5 summarises the variables used in each chapter of this thesis.   
Table 3.5: Summary of outcome factors, study factors, and covariates used in 
this thesis 
Chapter Outcome factors Study factors Covariates 





reported joint pain 
(yes / no), knee 
osteophytes, knee 
joint space narrowing 
Self–reported physician 
diagnosed rheumatoid 
arthritis, leg strength, age, 
sex, BMI 
5 Serum 25-OHD  
(Vitamin D)* 
WOMAC knee and hip 
pain  
Age, sex, BMI, season, 
leg strength, hip joint 
space narrowing, 
osteophytes, number of 
cartilage defects, 
presence of knee bone 
marrow lesions 
6 Knee pain (VAS)*, 









receive 4Jointz or 
placebo 
OARSI grade, sex 
7 Knee pain (VAS)*, 
KOOS pain scale*; 





acid or placebo 
Age, sex, baseline pain 
score, baseline pain 
medicine use 
*Measurement protocol described in “Methods” or “Patients and Methods” section of 
relevant chapter. 
AQoL: Assessment of Quality of Life instrument 
OARSI grade:  a classification of radiographic knee osteoarthritis 
VAS:  visual analog scale 
IL-6: interleukin 6, an inflammatory marker 
CTX-2:  C–terminal cross linking telopeptide of type 2 collagen, a marker of cartilage 
tissue degredation 
OARSI–OMERACT response critieria:  responder criteria defined by the relevant 
professional societies 





Table 3.6. Study populations used in this thesis 
Chapter Study Selection Source Recruitment 
location 




4,5 Tasmanian Older 








2002–08 50–80 P1:1099 
P2: 875 
P3: 769 
6 A randomised 
controlled trial of 
Arthritis Relief Plus 
for osteoarthritis of 









Clinical knee OA, 
Knee pain on most 
days,  
VAS pain score ≥40 
mm 
2011 >50 133 











Clinical knee OA, 
Knee pain on most 
days,  
VAS pain score ≥40 
mm, 
bone marrow lesion 
2009–10 >50 59 
†Age (years) at enrolment  
VAS: visual analog score 
P1, P2, P3:  The three phases of TASOAC, phases 1, 2 and 3, representing baseline, 2.6 year follow up and 5 year follow up 
 




3.7 Statistical analysis 
T-tests and 2 tests were used to compare differences in means and 
proportions as appropriate.  Statistical significance was determined using 
=0.05 and two –tailed tests throughout the thesis.  Detailed descriptions of 
statistical analyses performed are presented in the relevant data chapters.  
All statistical analyses were performed on Stata 10 – 12 for Windows 
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Chapter 4. A prospective study of the impact of 
musculoskeletal pain and radiographic osteoarthritis 
on health related quality of life in community 
dwelling older people 
This manuscript has been published (Laslett et al BMC Musculoskelet Disord. 
2012;13:168).  The typeset version of the manuscript as it appeared in the 
journal is in Appendix 4. 
The text of this chapter is the same as the published version, except where 
changes have been requested by the examiners.  Therefore there is some 
repetition of the methods, some of which appear in more detail in Chapter 3. 
4.1 Introduction 
Quality of life (QoL) is a useful and widely–used measure of health status 
because it captures the personal and social context of patients’ lives in a 
quantifiable way, and predicts use of health care resources and mortality (Dorr, 
2006; Singh, 2005).  Osteoarthritis (OA) is a leading cause of disability amongst 
older adults, and persons with osteoarthritis typically score poorly on QoL 
measures.  Aspects of QoL involving physical functioning and pain are the most 
affected, and patients who report pain typically report it at more than one 
site (Croft, 2005).  Number of sites of pain have been associated with 
increasing disability (Croft, 2005) and poorer overall health, sleep quality and 
psychological health (Kamaleri, 2008).  However, it is unclear whether pain at 
different sites is additive in terms of effect on QoL.  Radiographic markers of 
osteoarthritis are weakly associated with pain (Bedson and Croft, 2008; 
Hannan, 2000) but both are associated with poor QoL, and it is unclear if 
radiographic findings are independent of a diagnosis of OA, or pain (Kim, 2010; 
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Muraki, 2011; Norimatsu, 2011).  In addition, it is not known whether the cross–
sectional associations track over time.  Baseline back, knee and hip pain were 
associated with reducing QoL over four years of observation in a Chinese 
volunteer cohort (Woo, 2009) but this has not been reported in western 
populations, in other anatomical sites, or in a population which also has 
radiographic measures. 
The aim of this study was to describe the association between osteoarthritis and 
QoL in a community dwelling population–based sample of older people over five 
years.   
4.2 Patients and methods 
4.2.1 Participants 
The Tasmanian Older Adult Cohort (TASOAC) is an ongoing, prospective, 
population–based study examining the determinants of osteoarthritis and 
osteoporosis in older community dwelling adults.  Men and women aged 50–80 
years in 2002 were selected from the electoral roll in Southern Tasmania 
(population 229,000) using sex–stratified simple random sampling without 
replacement (response rate 57%).  Participants were excluded if they resided in 
an aged care facility.  The research was approved by the Southern Tasmanian 
Health and Medical Human Research Ethics Committee and written informed 
consent was obtained from all participants.  Participants attended clinic and 
completed questionnaires.  Data collection included blood sampling, magnetic 
resonance (MR) imaging (not reported in this study), knee and hip X–ray and 
other correlates of knee and hip OA and osteoporosis. Baseline data (Phase 1) 
was collected from February 2002 to September 2004.  Follow up data (Phase 
2 and 3) was collected on average 2.6 (range 1.4 to 4.8) and 5 years (range 3.6 
to 6.9 years) later.  Participants who did not have an MRI at Phase 1 (n= 105) 
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were excluded from further participation in the study, as TASOAC aimed to 
measure osteoarthritis progression.   
4.2.2 Quality of life 
Health–related QoL was measured using the Assessment of Quality of Life 
(AQoL) questionnaire (Hawthorne, 2000).  This is a generic QoL instrument with 
five subscales (Illness, Independent Living, Social Relationships, Physical 
Senses and Psychological Well–being), each with three items with four 
response levels (scored 0–3 for each item).  The AQoL is a valid measure of 
QoL (Osborne, 2003) and is reliable in population–based settings (Cronbach’s α 
= 0.81)  (Hawthorne and Osborne, 2005).  The AQoL was used as an 
unweighted, psychometric instrument providing ‘value’ profiles, rather than 
using the utility measures (Hawthorne, 2000) such as the AQoL–4D.  These use 
only four of the subscales, excluding the Illness subscale which includes 
questions about the use and reliance on prescribed medicines or medical aids 
and requirement for regular medical treatment, all of which are likely to be 
increased by pain or a diagnosis of OA.  Total scores for each subscale 
therefore ranged from 0–9 and the total instrument 0–45, with higher scores in 
each scale indicating worse QoL.   
4.2.3 Physician diagnosed osteoarthritis, pain and rheumatoid arthritis 
Participants completed questionnaires (n=1099) which asked “Have you had 
been told by a doctor that you have osteoarthritis at any of these sites”, and “Do 
you experience pain at any of these sites?".  The seven anatomical sites were 
neck, back, hands, shoulders, hips, knees, and feet.  Participants were given 
the choice between answering "yes" or "no".  Participants were also asked 
“Have you been told by a doctor that you have rheumatoid arthritis?” (yes / no).  
Questions were asked about pain at Phase 1, 2 and 3; doctor diagnosed OA at 
Phase 1 and 2, and about doctor diagnosed RA at Phase 1. 




Participants had X–rays of both hips (n=1014) and knees (n=1020) in the 
standing anterio–posterior (AP) position at baseline only.  Knee X–rays were 
taken of both knees with 15° of fixed knee flexion, and pelvic radiographs with 
both feet in 10° internal rotation.  Films were scored individually for osteophytes 
and joint space narrowing (JSN) on a scale of 0–3 (where 0=no disease and 
3=most severe disease) according to the Osteoarthritis Research Society 
International (OARSI) atlas (Altman, 1995) as previously described (Foley, 
2006).  Hips and knees with scores 1–3 at any site were classified as having 
JSN or osteophytes.  Two readers simultaneously assessed radiographs with 
immediate reference to the atlas.  Scores for each participant were determined 
by consensus.  Intraobserver repeatability was assessed in 40 participants 
(intraclass correlation coefficients (ICCs) 0.65 to 0.85 for the knee and 0.60– 
0.87 for the hip)  (Foley, 2006). 
4.2.5 Other factors 
Leg strength (n=1038) was measured to the nearest kilogram in both legs 
simultaneously, using a dynamometer (TTM Muscular Meter, Tokyo, Japan) as 
described in Scott, 2009a (Scott, 2009).  This tests isometric strength, 
predominantly of the quadriceps and hip extensors.  Weight was measured to 
the nearest 0.1 kg (with shoes, socks, bulky clothing and headwear removed) 
using a single pair of calibrated electronic scales (Seca Delta Model 707).  
Height was measured to the nearest 0.1 cm (barefoot) using a stadiometer. 
Body mass index (BMI) was calculated [weight (kg)/(height (m))2].  Physical 
activity levels were determined using pedometers (Omron HJ–003 & HJ–102; 
Omron Healthcare, Kyoto, Japan) as previously described (Scott, 2009).  
Briefly, number of steps per day is an average of seven consecutive days and 
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averaged across two time points in different seasons.  We collected self–
reported estimates of current cigarette smoking prevalence by questionnaire.   
4.2.6 Data analysis 
We used Stata 10.0 (StataCorp LP) for statistical analyses.  Statistical 
significance was set as a p value ≤0.05 (two–tailed).  Sample characteristics 
were analysed using t–tests and chi–square tests as appropriate.  Analyses 
used total AQoL score as the outcome, and diagnosed OA, JSN, osteophytes 
and pain as co–predictors.  Baseline data was analysed using multiple linear 
regression.  Analyses were first adjusted for age, sex and body mass index 
(BMI) (Step 1); variables which demonstrated a statistically significant 
association with total AQoL score were put into the next analysis, with the 
confounders leg strength and RA.  The purpose of this was to determine 
whether each factor was independently associated with QoL or whether they 
were no longer significant after adjusting for other factors, suggesting mediation 
of effect.   
Multilevel mixed–effects linear regression were used for longitudinal analyses, 
clustering on ID, and adjusted for change in BMI and age over time, as these 
terms were statistically significant.  These were intent to treat analyses and 
used all available data. 
We transformed the total AQoL score using a square root transformation in 
order to meet the residual assumptions underlying linear regression.  
Regression coefficients were back–transformed, and the β value was reported 
for each dependent variable, calculated with all other continuous variables 
centred at their mean, and dichotomous variables with the reference group 
having a value of zero.  As a sensitivity analysis, we re–ran models in Table 3 
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without the psychological wellbeing scale to assess the possible effects of 
psychological distress as an unmeasured confounder of QoL.  






A total of 1098 people (51% female, mean age 63.0 years) completed baseline 
questionnaires.  Of the 993 participants with complete MRI data at Phase 1 and 
were therefore invited to return for Phase 2, 875 completed Phase 2 and 768 
completed Phase 3.  Participants who failed to complete Phase 2 or 3 (including 
those who did not have baseline MR imaging), were older, had higher BMI and 
pain at more sites at baseline than those who remained in the study.  
4.3.2 Characteristics of the study population at baseline 
Table 1 displays the characteristics of the cohort at baseline, stratified by 
median AQoL score.  Those with poorer QoL were older, had higher BMI, 
walked fewer steps per day, were more likely to be retired or receiving a 
disability pension and less likely to be employed; and more likely to have no 
formal educational qualifications (Table 1).   
  




Table 4.1: Characteristics of the study population at baseline, by quality of life† 
 QoL better than 
median 
Mean ± SEM 
n (%) 
n= 525 
QoL at median or 
worse 




Age (years) 61.9 ± 0.3 64 ± 0.3 <0.001 
Gender (% male) 51 47 0.176 
BMI weight (cm) / (height (m))2 27.3 ± 0.2 28.4 ± 0.2 <0.001 
Height (cm) 167.7 ± 0.4 166.3 ± 0.4 0.006 
Weight (kg) 77 ± 0.6 78.7 ±0.6 0.060 
Current smokers (%) 12 12 0.782 
Number of steps per day 10373.9 ± 158.3 8597.9 ±154.7 <0.001 
Education Level   <0.001 
     No formal qualification 54 (10) 126 (22)  
     School or Intermediate 
certificate 
104 (20) 114 (20)  
     Higher School or Leaving 
Certificate 
114 (22) 107 (19)  
     Trade / apprenticeship 59 (11) 78 (14)  
     Certificate / diploma 122 (23) 95 (17)  
     University degree or higher 72 (14) 52 (9)  
Current employment    
     Employed / self–employed  
    (full or part time) 
264 (50) 168 (29) <0.001 
     Retired 178 (34) 240 (42)  
     Disability pension 4 (0.8) 69 (12)  
Doctor–diagnosed rheumatoid 
arthritis (%) 
6 18 <0.001 
Leg strength (kg) 101.6 ± 1.38 86.3 ± 1.4 <0.001 
† QoL was not normal and hence dichotomized at the median. 
 
They also had higher prevalence of diagnosed osteoarthritis (OA) and pain at all 
sites (Table 4.3).   
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Health–related QoL scores at baseline were skewed with a mean AQoL score 
of 7.4 (SD 4.9) and a median of 7.0 (range 0 to 29).  Summary results for 
individual subscales are shown in Error! Reference source not found.. 
Table 4.2: Assessment of Quality of Life (AQoL)† subscales at baseline: mean 








Illness 3.2 (2.6) 3 0 – 9 
Independent Living 0.3 (0.9) 0 0 – 7 
Relationships 0.7 (1.0) 0 0 – 8 
Physical senses 0.9 (1.0) 1 0 – 5 
Psychological wellbeing 2.3 (1.6) 2 0 – 9 
Total AQoL score 7.4 (4.9) 7 0 – 29 
†Higher scores indicate poorer QoL 
Distribution was skewed and kurtotic, hence analyses are 
transformed using a square root transformation, with back 
transformed results presented 
 
  





Table 4.3: Osteoarthritis correlates of total AQoL score at baseline, using linear 
regression 
 Prevalence       
% 
Step 1:  
Multivariable β                
(95% CI) 
Adjusted for age, 
sex and BMIf 
Step 2:  
Multivariable β               
(95% CI)§ 
Further adjusted for all 
variables significant in 
Step 1 
Diagnosed OA of:    
Neck 168 (15) 2.72 (1.80 to 3.64) -0.32 (-0.96 to 0.32) 
Shoulders 193 (18) 3.58 (2.34 to 4.81) 0.23 (-0.64 to 1.10) 
Back 167 (15) 3.41 (2.54 to 4.28) 0.71 (0.02 to 1.41) 
Hips 97 (9) 3.05 (1.93 to 4.17) 0.04 (-0.74 to 0.82) 
Hands 113 (10) 2.32 (1.41 to 3.23) 0.09 (-0.55 to 0.72) 
Knees 152 (14) 2.48 (1.52 to 3.43) 0.15 (-0.55 to 0.85) 
Feet 103 (9) 3.40 (2.21 to 4.59) 0.30 (-0.49 to 1.09) 
Hip JSN (yes / no) 377 (37) 0.34 (-0.31 to 0.99) – 
Knee JSN (yes / no) 688 (67) 0.06 (-0.60 to 0.72) – 
Hip osteophyte  
(yes / no) 
190 (19) -0.10 (-0.89 to 0.69) – 
Knee osteophyte 
(yes / no) 
143 (14) -0.31 (-1.21 to 0.59) – 
Pain in the:    
Neck  (yes / no) 514 (47) 3.14 (2.58 to 3.71) 0.65 (0.16 to 1.15) 
Shoulder  (yes / no) 674 (62) 3.35 (2.77 to 3.93) 1.03 (0.52 to 1.54) 
Back  (yes / no) 481 (44) 2.94 (2.39 to 3.50) 0.58 (0.12 to 1.05) 
Hip  (yes / no) 481 (44) 2.44 (1.83 to 3.04) 0.26 (-0.18 to 0.70) 
Hand  (yes / no) 505 (46) 2.63 (2.05 to 3.22) 0.50 (0.04 to 0.96) 
Knee  (yes/no) 451 (41) 2.72 (2.13 to 3.31) 0.41 (-0.04 to 0.86)  
Foot  (yes / no) 412 (38) 3.27 (2.64 to 3.89) 1.13 (0.62 to 1.63) 
Statistically significant (p≤0.05) results indicated in bold type 
f after adjustment for age, sex and BMI 
§ further adjusted for diagnosis of RA, arthritis at all sites or pain at all sites and leg 
strength 
§ R2 for final model (Step 2)=27%; R2 excluding pain is 13%; R2 pain alone=23%. 
 
Diagnosis of RA and leg strength were also associated with QoL, as expected, 
(Table 4.1), and were adjusted for in final models.  Pain at the anatomical 
regions of interest was common (prevalence 38–62%), with 87% of participants 
reporting pain in at least one joint.  8% of patients reported pain in all seven 
regions. 
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4.3.3 Correlates of quality of life at baseline: cross–sectional analysis 
Since presence of pain at the various sites was not strongly collinear, 
(Pearson’s correlation r= 0.21 – 0.51), individual sites were entered into the 
model separately.   
Table 4.3 shows that physician diagnosis of OA at any of the sites was 
associated with poorer QoL after adjustment for age sex and BMI, but only 
physician diagnosed OA of the back remained significant after further 
adjustment for RA, diagnosed OA at other sites and pain.  Radiographic OA of 
the hip or knee (JSN, osteophytes) were not associated with QoL in any 
analysis.  Presence or absence of pain at five of the seven sites were 
independently associated with poor QoL after further adjustment for diagnosis 
of RA, leg strength, diagnosed OA and pain at other sites.  Knee pain was of 
borderline statistical significance after adjustment for all correlates, p=0.076), 
and hip pain was not significant.   
The proportion of variance explained by the final model (R2, n=1017) was 27%, 
of which 23% was explained by pain.  There was also a strong linear 
association between the number of sites at which participants reported pain and 
QoL (Figure 4.1), suggesting a dose–response relationship.  This association 
was significant at all three time points, and relatively constant over time 
(interaction p=0.602). 




Figure 4.1: Mean total Assessment of Quality of Life (AQoL) score over time, by 
number of sites at which participants report pain and using multilevel mixed–
effects linear regression 
 
We conducted sensitivity analyses without the psychological wellbeing subscale 
in order to assess whether the results from our total AQoL score were still valid 
after removing questions related to psychological factors.  The same variables 
remained significant and coefficients were similar.   
  




4.3.4 Correlates of quality of life over time: Longitudinal analysis  
Mean AQoL scores were 7.36 (95% CI 7.07 – 7.65) at Phase 1, 7.53 (95% CI 
7.20 – 7.87) at Phase 2 and 7.82 (95% CI 7.47 – 8.17) by Phase 3.  Average 
AQoL scores had significantly worsened by Phase 3 (p=0.047), but not Phase 2 
(0.44) using unadjusted data and unpaired t–tests.  After adjusting for the 
changing composition of the sample over time using linear mixed models, 
reduction in means was significant at both Phase 2 and 3 (p<0.001). 
Table 4.4 shows a similar pattern of correlates of QoL to the analysis of 
correlates at baseline, although most effect sizes were smaller.   
After 2.6 years of observation, diagnosed OA (all sites) and presence or 
absence of pain (all sites) were significant.  After further adjustment for the 
factors outlined above, diagnosed OA at the back remained significant as did 
pain at six of the seven anatomical sites.  There were no significant interaction 
terms after adjustment for confounders and other covariates. 
After five years of observation, pain at all sites was a significant independent 
determinant of QoL (Table 4.4).  QoL amongst participants with neck pain 
remained stable whilst steadily worsening in those with no neck pain (p=0.02 for 




Table 4.4:  Longitudinal analysis of arthritis correlates of total AQoL score over five years of follow up, using multilevel mixed–effects 
modelling 
 Baseline to Phase 2 
(2.6 year follow up) 
Baseline to Phase 3 
(5 year follow up) 
 Step 1:  
Multivariable  
(adj. age sex BMI, 
change in BMI and 
age over time) 
Step 2:  
Multivariable  
Adjusted further¥ 
Step 1:  
Multivariable  
(adj. age sex BMI, 
change in BMI and 
age over time) 
Step 2:  
Multivariable  
Adjusted further 
Diagnosed OA of:     
    Neck 1.55 (0.96 to 2.15) 0.01 (-0.5 to 0.52)   
    Shoulders 1.92 (1.22 to 2.61) 0.37 (-0.23 to 0.96)   
    Back 1.76 (1.23 to 2.28) 0.59 (0.12 to 1.06)   
    Hips 1.19 (0.54 to 1.84) -0.20 (-0.73 to 0.32)   
    Hands 1.35 (0.79 to 1.90) 0.19 (-0.28 to 0.66)   
    Knees 1.50 (0.91 to 2.08) 0.15 (-0.34 to 0.64)   
    Feet 1.40 (0.72 to 2.09) 0.12 (-0.44 to 0.68)   
Presence or absence of pain in the:    
    Neck 1.79 (1.4 to 2.18) 0.55 (0.19 to 0.91) 1.20 (0.89 to 1.51) 0.42 (0.14 to 0.71) 
    Shoulders 1.80 (1.42 to 2.18) 0.66 (0.31 to 1.00) 1.36 (1.06 to 1.66) 0.64 (0.36 to 0.91) 
    Back 1.82 (1.45 to 2.19) 0.67 (0.33 to 1.00) 1.39 (1.09 to 1.68) 0.66 (0.39 to 0.94) 
    Hips 1.46 (1.07 to 1.85) 0.52 (0.19 to 0.85) 1.16 (0.85 to 1.47) 0.47 (0.20 to 0.74) 
    Hands 1.20 (0.82 to 1.59) 0.19 (-0.13 to 0.51) 0.91 (0.60 to 1.22) 0.27 (0.01 to 0.53) 
    Knees 1.51 (1.12 to 1.90) 0.43 (0.10 to 0.75) 1.10 (0.79 to 1.41) 0.44 (0.17 to 0.70) 
    Feet 0.98 (0.65 to 1.32) 0.36 (0.09 to 0.62) 0.75 (0.47 to 1.02) 0.26 (0.03 to 0.49) 
Statistically significant (p≤0.05) results indicated in bold type 
¥ Results further adjusted for diagnosed OA at all sites, pain at all sites, presence of rheumatoid arthritis and leg strength 
Results further adjusted as for the analyses for Baseline to Phase 2, but without Diagnosed OA as this was not asked at Phase 3.   
5 year follow up data includes data collected at Phase 1, 2 and 3 and is not limited to participants with complete data. 
Radiographs not included as they were only collected at Phase 1. 





This population–based prospective study describes the contribution of 
multiple osteoarthritic correlates of QoL over five years of observation.  
Physician diagnosed OA of the back and pain at all sites were independent 
and stable correlates of QoL, and pain at multiple sites has an additive 
deleterious effect on QoL.  With the exception of the back, pain appeared to 
mediate the association between diagnosed OA and QoL. Radiographic 
osteoarthritis was not associated with QoL.   
In this study, the strongest musculoskeletal correlate of QoL was pain.  Pain 
is a priority for patients seeking care (Heiberg and Kvien, 2002) and thus it is 
perhaps not surprising that pain largely mediated the association between 
doctor diagnosed OA and QoL.  Further, pain assessed at one site in cross 
sectional studies is known to be associated with poorer QoL (Hill, 2008; 
Rezai, 2009), but no studies that have looked at pain at many sites. Our data 
suggests that pain at all sites measured independently contribute to QoL, 
there is a dose response association between number of pain sites and QoL, 
and severity of pain is also related to QoL.  Our data suggests that pain is 
very common in older adults in the community.  Given that pain at individual 
joints and overall number of sites of joint pain were associated with poor 
QoL, this suggests that interventions to reduce the frequency and intensity of 
pain may be effective in improving QoL at the population level. 
While there are some inconsistencies in the three analyses, the most weight 
should be put on the analysis over five years as it uses all the data and 
therefore is the most powerful.  These results confirm and extend the findings 
of Woo et al (2009), where pain at the back, hip (men only) and knees was 
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associated with QoL over time in ethnic Chinese.  Pain in the shoulders and 
back were the most important factors in our analyses, but knees, hips and 
even hands and feet were significant.  The inconsistency with the hip may, in 
part, be due to patients have difficulty locating the correct anatomical position 
of the hips (Birrell, 2005), or that pain in the knee can actually be referred 
from the hip (Zhai, 2006).  Knee pain was of borderline significance in cross–
sectional analyses but became significant over time.   
Diagnosed OA of the back was also an independent correlate of poor QoL 
(both in cross–sectional and longitudinal analyses), but diagnosed OA of the 
neck, shoulders, hips, hands, knees and feet were not once adjustment was 
made for the multiple sites of OA and for pain.  This suggests that while pain 
mediates the associations between diagnosed OA and QoL at sites other 
than the back (neck, shoulders, hands, hips, knees and feet), the association 
between diagnosed OA of the back and QoL is only partially mediated by 
pain. It is well known that psychological factors such as depression are 
associated with chronic back pain but unfortunately we were not able to 
assess these in the current study.   
There was no association between radiographic osteoarthritis and QoL at 
baseline, after adjusting for age, sex and BMI.  This suggests that 
radiographic findings make no independent contribution to QoL, consistent 
with other studies which showed that the association between radiographic 
OA of the hand and function was largely mediated by pain (Jones, 2001), and 
that pain is a better predictor of disability than radiographic change (Creamer, 
2000; Guccione, 1990; Jordan, 1997).  This differs from the findings of other 
studies (Norimatsu, 2011; Muraki, 2011), who found that radiographic OA 
was associated cross–sectionally with different disease–specific measure of 
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QoL, after adjustment for pain and other covariates.  Both of these measures 
of QoL had pain as a subscale, so this may explain why they found an 
association yet we did not.  A strength of our study is that, unlike Norimatsu 
and colleagues, we have collected (self–reported) diagnosis of OA and 
radiographic findings separately (in addition to pain), and while finding them 
to be correlated, when both diagnosis and radiography appear together in 
one model, radiographic findings are no longer associated with QoL.  Our 
data demonstrates that diagnosis of OA reflects more than radiographic 
evidence of joint damage, but that with the exception of diagnosed OA of the 
back, is not independent of pain. 
Strengths of this study include the random population–based sampling and 
comprehensive data collection, and five–year period of observation, providing 
excellent external validity for our findings.  Limitations include absence of 
information on psychological factors, such as diagnosed mental health 
conditions or psychological distress: this limits our ability to consider such 
conditions as covariates or effect modifiers, but our model is robust whether 
or not the mental health component of QoL is included, suggesting this is not 
a major issue.  Additionally, the initial response rate of 57%, while lower than 
desirable, is similar to other comparable Australian studies (Hill, 2008), and a 
lower response rate does not mean that relationships between outcome and 
exposure are necessarily biased (Carter, 2012).  Participants who did not 
continue in the study were older, heavier, with pain at more sites at baseline 
than the remaining participants.  This should reduce the observed effect size 
of our findings, but since few associations were of borderline significance this 
should not have altered our conclusions. We did not seek to confirm doctor–
diagnosed cases of arthritis, and therefore participants may have under–or 
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over–reported diagnosed arthritis, and the extent to which this may have 
affected the findings of the study is unclear.  However, use of self–reported 
doctor diagnosed OA appears to be a reasonable proxy for OA, as JSN was 
more common in participants reporting doctor–diagnosed OA at the hips and 
knees (hips OR 2.3, p<0.001; knees OR 1.6, p=0.023), and osteophytes 
more common in participants reporting knee (OR 4.10, p<0.001), but not hip 
OA (OR 0.94, p=0.83).  We had X–rays only of the hips and knees, and so 
are not able to assess the association between ROA and QoL at other 
anatomic sites.  However, unless the causal pathways at other sites are 
substantially different to those at the knees and hips, it is unlikely that 
radiographic OA at these sites would add any new information to the models.  
In conclusion, pain is the strongest musculoskeletal correlate of QoL, which 
has an additive deleterious effect on QoL, and mediates the effect of 
diagnosed OA (except in OA of the back).  These associations are stable 
over time suggesting that pain has a consistent rather than an increasing 
deleterious effect.  Since we found that the same factors were associated 
with quality of life over time as in the baseline analysis, this suggests that 
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Chapter 8. Summary and future directions 
8.1 Introduction 
As has been described in this thesis, arthritis is the most common cause of 
chronic pain in older people (Peat, 2001; Britt, 2010), affecting an estimated 
31% of Australians (AIHW, 2010), and is expensive, constituting the fourth 
largest component of direct health expenditure in 2004–05, at AUD$4.0 
billion (AIHW, 2009).  Increases in expenditure are predicted to continue, and 
to increase by a factor of 2 by 2032–33 (Goss, 2008), driven by the ageing 
population the volume of treatment(s) for each person.  Pain is an important 
clinical symptom, predicting clinically relevant outcomes including 
disability (Croft, 2005) and joint replacement (Gossec, 2005; Hawker, 2006; 
Conaghan, 2010; Jüni, 2003), and is a priority for patients (Heiberg and 
Kvien, 2002).   
Despite the large disease burden, there are no proven preventative 
strategies, but there have been a few clinical trials in addition to the work 
presented in this thesis (Bruyere, 2008; Esenyel, 2012; Reginster, 2012), all 
using agents with well–described effects in bone.  None have demonstrated 
change in structural endpoints in addition to pain.  Conventional treatment of 
OA remains mostly palliative and expensive and there is considerable scope 
for improvements in treatments, both in terms of treatments which modify 
structure and pain, and safe treatments which confer additional pain benefits. 
8.2 Future directions 
8.2.1 Musculoskeletal pain and quality of life 
Investigations on the impact of musculoskeletal pain and radiographic OA on 
health related QoL in older adults living in the community are presented in 
Chapter 4.  We concluded that radiographic findings (JSN, osteophytes) 
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make no independent contribution to QoL, and that pain tracks over time.  
This supports a focus on pain–relieving interventions, and that reducing pain 
could change the trajectory of quality of life in the medium term.  Agents that 
slow structural progression of osteoarthritis are extremely important, but such 
agents must also improve pain if they are to improve the quality of people’s 
lives. 
8.2.2 Serum 25–OHD and change in knee and hip pain over time 
Investigations on associations between serum 25–OHD and change in knee 
pain over 5 years and change in hip pain over 2.6 years are presented in 
Chapter 5.  We found that there was no linear association between serum 
25–OHD and change in knee or hip pain using the original values of 25–
OHD, but that having serum 25–OHD below 25 nmol/L (moderately deficient) 
was a novel determinant of musculoskeletal pain.  Mild vitamin D deficiency 
is endemic in Tasmanian adults (van der Mei, 2012), as it is elsewhere in the 
world but moderate deficiency is uncommon in most populations  This study 
suggests that supplementation may help pain in this small subgroup but this 
needs to be tested in randomised trials before supplementation can be 
recommended, or guidelines developed for the use of supplements.  A 
randomised controlled trial of the effects of vitamin D in OA is underway at 
our centre (the Vitamin D Effects on OA, or VIDEO study (Cao, 2012)), in 
which vitamin D supplementation (50,000 IU compounded vitamin D3 
capsule monthly) or identical inert placebo is issued monthly to participants 
with symptomatic knee OA and serum 25–OHD of 12.5 – 60 nmol/L for two 
years.  Outcomes from the VIDEO study will include the effect of vitamin D3 
supplementation on pain, as measured by the WOMAC pain score.  
Therefore, the VIDEO study will be able to determine whether vitamin D 
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supplementation is effective in improving knee pain in persons with clinical 
knee osteoarthritis, and whether this effect is observed only in persons with 
baseline 25–OHD levels of 25–30 nmol/L or whether such benefits apply to 
all study patients (12.5 to 60 nmol/L).   
Two recent trials have demonstrated increased risk of fractures (Sanders, 
2010; Smith, 2007) and falls (Sanders, 2010) using large (300,000IU) annual 
intramuscular doses of vitamin D2 or vitamin D3.  This has overturned the 
previous view attained from studies with more frequent dosing regimes that 
vitamin D supplementation was safe as long as 25–OHD levels remained 
below the toxic levels of 275–500 nmol/L (Jones, 2008).  The results of these 
trials are a cautionary tale of the importance of randomised trials in 
determining efficacy and safety before treatments are introduced into clinical 
practise. 
8.2.3 4Jointz trial 
A randomised controlled trial of 4Jointz vs placebo was conducted (see 
Chapter 6).  We demonstrated that topical treatment using 4Jointz is a safe 
and effective treatment for the symptoms of knee OA in participants with 
clinical OA and moderate knee pain on most days. In particular, use of 
4Jointz reduced pain and increased muscle strength, but had no effect on 
systemic inflammation or cartilage breakdown over 12 weeks of treatment.  
This was particularly notable as these benefits were in addition to the effect 
of other treatments.   
We observed higher dropout rates in the group receiving 4Jointz, partially 
attributable to rashes (localised skin irritation at the site of application).  This 
highlights the importance of conducting clinical trials on all medications, as 
rashes were not reported as an adverse event in previous studies using 
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topical preparations of comfrey.  It is possible that rashes were related to the 
other components of 4Jointz, such as tannic acid.  The pharmaceutical 
company may consider how they can make the preparations less irritating in 
order to minimise rashes.   
Since post-hoc analyses suggested that treatment may be most effective in 
women and those with milder radiographic OA, future studies should 
consider including these populations, and for longer duration than 12 weeks.  
This trial also suggests the value of using add–on trials in OA, where a 
medication is given to patients in addition to their other medications. 
8.2.4 ZAP trial 
This trial Investigated the effect of a single dose of zoledronic acid (5mg) on 
persons with moderately severe knee pain, clinical knee OA and BMLs (see 
Chapter 7). Use of ZA significantly reduced VAS pain scores, areal size of 
BMLs after 6 months, and proportion with improvement in BML size.  This is 
the first occasion that any osteoarthritic treatment has demonstrated 
structural modification of BMLs (or indeed any other structure); therefore this 
observation is completely novel.  Previous investigations of potential 
structure–modifying drugs did not live up to expectations (Bingham, 2006; 
Raynauld, 2008).  For ZA to be truly disease modifying, evidence of change 
in cartilage endpoints or joint replacement will be required.  To this end, our 
research group have been successful in obtaining a National Health and 
Medical Research Council Project Grant (2012 Application ID 1045415).  
This will fund a two year randomised controlled trial of yearly infusion of ZA 
(5mg) on cartilage volume, along with other endpoints collected in the shorter 
trial presented as part of this thesis (BMLs, pain, function) as well as cartilage 
markers and joint replacement.  
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One of the observations from the ZAP trial was that 39% of participants 
receiving ZA improved, whereas only 18% receiving placebo improved, 
representing an odds ratio of 5.0 (p=0.044).  This is a significant difference, 
showing that ZA is effective in reducing the size of BMLs, with large enough 
reductions that we expected to observe a clinically significant reduction in 
pain.  However, even in the group who received ZA, 61% had an increase in 
their BMLs or no change (compared to 82% in the placebo group).  Clearly 
some patients are responding to treatment whereas others are not.  Since 
the pathology of BMLs are heterogeneous (Zanetti, 2000; Taljanovic, 2008), 
one of the explanations for this is that some histological profiles respond to 
osteoclast–mediated ZA therapy whereas others do not.  Unfortunately, no 
markers are yet available for typing of BMLs using non-invasive methods, as 
biopsies are not feasible in this population.  Similarly, some participants had 
evidence of reduction in the size of BMLs but not reduction in pain, which we 
attribute to presence of other pathologies which cause pain, such as joint 
effusions.  In the new, NHMRC–funded two–year RCT with cartilage 
endpoints which will begin in 2013, we plan to investigate the effect of other 
pathology and disease characteristics on response to ZA. 
This clinical trial also provides evidence of a “bone-specific” phenotype of 
OA (Walsh and Chapman, 2011) which is highly likely to be responsive to 
treatment with bisphosphonates. 
8.2.5 Challenges in clinical trials in osteoarthritis 
8.2.5.1 Choice of study patients 
Animal models suggest that synovitis and BMLs are very early signs of OA, 
preceding cartilage erosion and degeneration (Libicher, 2005); thus these 
may be optimal markers to target in achieving disease modification, as they 
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occur early in the disease course when less damage has occurred.  Yet 
typical patients in knee OA trials with structural endpoints are patients with 
much later stages of OA, ie Kellgren and Lawrence grade 2 and 3.  
Intervening earlier in the disease course is always preferable, but additionally 
choosing patients with radiographic OA for interventional studies has 
additional problems, as the presence of radiographic OA predicts patients 
who lose cartilage faster (Mazzuca, 2005; Saunders, 2011), and this has 
implications for participant selection in clinical trials as the outcomes of 
treating these different Oa phenotypes may have different outcomes.  This 
suggests that selection of study patients is crucial when planning intervention 
studies, and in evaluating their results. 
8.2.5.2 Choice of outcome measures 
Change in joint space width (JSW) at the tibiofemoral joint is currently the 
gold standard for assessing osteoarthritis disease modification in clinical 
trials, (Conaghan, 2011) and is mandated by the Food and Drug 
Administration and European Medications Agency as a proxy endpoint to 
determine efficacy of disease modifying osteoarthritis drugs.  In cross-
sectional studies, the amount of cartilage volume assessed by magnetic 
resonance imaging (MRI) and JSW as assessed by radiograph are strongly 
correlated. However, JSW is also associated with meniscal 
pathology  (Berthiaume, 2005; Adams, 1999) and cartilage defects, (Ding, 
2005) suggesting that multiple abnormalities contribute to narrowing of joint 
space width (JSW).  There is limited longitudinal data; however data from our 
centre demonstrates that both change in cartilage volume and meniscal 
extrusions modestly predict change in joint space width; however, over 90% 
of the variation in change in joint space remains unexplained (Hall, 2012).  
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Using MR imaging in preference to radiographs should be a better outcome 
measure as it enables direct (vs indirect) visualisation of these structures, 
and has been validated in cadaveric studies, (Cicuttini, 1999) and predicts 
clinical outcomes such as joint replacement (Cicuttini, 2004).  Overall, 
cartilage loss seen on MRI is more sensitive than X-ray change as an 
outcome measure.   
There are other issues in using radiographs as outcomes.  Structures seen 
on radiographs may not be direct sources of pain, and therefore are of limited 
value in assessing factors causing pain.  Also, the changes in JSW in some 
trials (even large trials) have shown mean changes that were less than the 
measurement error of the technique of evaluation}, despite large numbers of 
patients and state of the art protocols. (Brandt, 2005; Bingham, 2006) 
Despite these shortcomings, MR imaging is yet to replace radiographs as 
routine an outcome measures in studies investigating structural outcomes.   
8.2.5.3 Subtypes or phenotypes of osteoarthritis 
Osteoarthritis can result from an extremely diverse range of pathologies and 
pathological processes, resulting in a heterogeneous mix of pathological 
processes and tissue subtypes amongst patients diagnosed with OA.  This 
creates a challenge for clinical trials in that a treatment applied to a particular 
study group may only be effective in a small subset of that group.  Therefore, 
separating study populations into subgroups with particular features that are 
likely to respond (or not respond) to particular treatments have 
advantages (Lane, 1999).  One such phenotype is a “bone–specific 
phenotype” (Walsh and Chapman, 2011) in patients with BMLs.  Bone 
marrow lesions identify regions of increased subchondral bone turnover and 
therefore may provide a biomarker that can predict response to 
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bisphosphonates.  Phenotypes postulated by other authors are post-
traumatic (acute or repetitive), metabolic, ageing, genetic and pain (Bijlsma, 
2011), and rate of progression or prognosis (Lane, 1999); each with different 
aetiological features, causal pathways, affected sites and effective 
treatments.  Identifying subtypes or phenotypes of OA is likely to assist in 
targeting treatment to patients who are the most likely to benefit. 
8.2.6 Conclusions 
In conclusion, this analysis of data from a prospective population–based 
cohort study and two randomised controlled trials demonstrate that pain is an 
independent correlate of quality of life, that one of the determinants of knee 
(and possibly hip) pain over time is moderate vitamin D deficiency, and that 
treatment of patients with clinical knee OA and pain on most days with either 
ZA infusion or application of 4Jointz reduces knee pain.  Most importantly, we 
have demonstrated that ZA may be a disease–modifying OA drug which 
reduces the size of BMLs in addition to reducing pain.  Future work is 
underway on larger multicentre clinical trials. 
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Appendix 1 Questionnaires 
 
A1.1 The Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC), and questions on diagnosed 
OA and joint pain 
  













A1.2 Smoking questions 
 
  













A1.3 Assessment of quality of life (AQoL) 
 
  
     ID______ 
 








1.Concerning my use of prescribed medicines:  
 
A.I do not or rarely use any medicines at all.  
B.I use one or two medicinal drugs regularly.  
C.I need to use three or four medicinal drugs regularly.  
D.I use five or more medicinal drugs regularly.  
 
 
2.To what extent do I rely on medicines or a medical aid? (NOT glasses or a 
hearing aid.) (For example: walking frame, wheelchair, prosthesis etc.)  
 
A.I do not use any medicines and/or medical aids.  
B.I occasionally use medicines and/or medical aids.  
C.I regularly use medicines and/or medical aids.  
D.I have to constantly take medicines or use a medical aid.  
 
 
   3.Do I need regular medical treatment from a doctor or other health 
professional? 
  
A.I do not need regular medical treatment.  
B.Although I have some regular medical treatment, I am not dependent on 
this.  
C.I am dependent on having regular medical treatment.  
D.My life is dependent upon regular medical treatment.  







4.Do I need any help looking after myself?  
 
A.I need no help at all 
B.Occasionally I need some help with personal care tasks.  
C.I need help with the more difficult personal care tasks.  
D.I need daily help with most or all personal care tasks.  
 
 
5.When doing household tasks: (For example, preparing food, gardening, 
using the video recorder, radio, telephone or washing the car)  
 
A.I need no help at all.  
B.Occasionally I need some help with household tasks.  
C.I need help with the more difficult household tasks.  
D.I need daily help with most or all household tasks.  
 
 
6.Thinking about how easily I can get around my home and community: 
  
A.I get around my home and community by myself without any difficulty.  
B.I find it difficult to get around my home and community by myself.  
C.I cannot get around the community by myself, but I can get around my 
home with some difficulty.  






7.Because of my health, my relationships (for example: with my friends, 
partner or parents) generally:  
 
A.Are very close and warm.  
B.Are sometimes close and warm.  
C.Are seldom close and warm.  
D.I have no close and warm relationships.  
 
 
8.Thinking about my relationship with other people:  
 
A.I have plenty of friends, and am never lonely.  
B.Although I have friends, I am occasionally lonely.  
C.I have some friends, but am often lonely for company.  
D.I am socially isolated and feel lonely.  





9.Thinking about my health and my relationship with my family:  
 
A.My role in the family is unaffected by my health.  
B.There are some parts of my family role I cannot carry out.  
C.There are many parts of my family role I cannot carry out.  





10.Thinking about my vision, including when using my glasses or contact 
lenses if needed:  
 
A.I see normally.  
B.I have some difficulty focusing on things, or I do not see them sharply. 
   For example: small print, a newspaper, or seeing objects in the distance.  
C.I have a lot of difficulty seeing things. My vision is blurred.  
   For example: I can see just enough to get by with.  
D.I only see general shapes, or am blind. For example: I need a guide to 
move around.  
 
 
11.Thinking about my hearing, including using my hearing aid if needed:  
 
A.I hear normally.  
B.I have some difficulty hearing or I do not hear clearly. 
   For example: I ask people to speak up, or turn up the TV or radio volume.  
C.I have difficulty hearing things clearly. For example: Often I do not    
understand what is said. I usually do not take part in conversations because I 
cannot hear what is said.  
D.I hear very little indeed. For example: I cannot fully understand loud voices 
speaking directly to me.  
 
 
12.When I communicate with others: (For example: by talking, listening, 
writing or signing)  
 
A.I have no trouble speaking to them or understanding what they are saying.  
B.I have some difficulty being understood by people who do not know me. I 
have no trouble understanding what others are saying to me.  
C.I am only understood by people who know me well. I have great trouble 
understanding what others are saying to me.  
D.I cannot adequately communicate with others.  











13.If I think about how I sleep:  
 
A.I am able to sleep without difficulty most of the time.  
B.My sleep is interrupted some of the time, but I am usually able to go back to 
sleep without difficulty.  
C.My sleep is interrupted most nights, but I am usually able to go back to 
sleep without difficulty.  
D.I sleep in short bursts only. I am awake most of the night.  
 
 
14.Thinking about how I generally feel:  
 
A.I do not feel anxious, worried or depressed.  
B.I am slightly anxious, worried or depressed.  
C.I feel moderately anxious, worried or depressed.  
D.I am extremely anxious, worried or depressed.  
 
 
15.How much pain or discomfort do I experience?  
 
A.None at all.  
B.I have moderate pain.  
C.I suffer from severe pain.  
D.I suffer unbearable pain.  
 
 
Hawthorne & Richardson (1996) All rights reserved.  
Assessment of Quality of Life (AQoL) instrument. Melbourne, Centre for 
Health Program Evaluation. 
The AQoL may not be copied or used without permission.  




A1.4 Knee Injury and Osteoarthritis Scale  
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Objective:  To assess the efficacy of thrice daily topical 4Jointz utilizing 
Acteev technology (a novel and patented combination of a standardized 
comfrey extract and a pharmaceutical grade tannic acid, 3.5 g/day), or 
placebo on osteoarthritic knee pain, markers of inflammation and cartilage 
breakdown over twelve weeks in a double-blind randomised controlled trial. 
Patients and methods:  Adults aged 50-80 years (n=133) with clinical knee 
osteoarthritis (OA) according to the ACR criteria were randomised to receive 
either 4Jointz or placebo in addition to existing medications.  Pain and knee 
function were measured using a visual analogue scale (VAS) and the Knee 
Injury and Osteoarthritis Outcome Score (KOOS) scale at baseline, 4, 8 and 
12 weeks.  Inflammation was measured using IL-6 and cartilage breakdown 
measured using CTX-2, at baseline and twelve weeks. 
Results:  Pain scores were significantly reduced in the group who received 
4Jointz compared to the group who received placebo after twelve weeks 
using both the VAS (-9.9mm, p=0.034) and the KOOS pain scale (5.7, 
p=0.047).  This effect decreased markedly within 4 weeks of cessation of 
treatment. In addition, muscle strength improved compared to placebo (+2.9 
kg, p=0.02) after twelve weeks. Changes in IL-6 and CTX-2 were not 
significant (+0.1, p=0.98; -23.0, p=0.44).  Reduction in paracetamol daily 
dose in patients using paracetamol at baseline was clinically (but not 
statistically) significant by twelve weeks (-404 mg, p=0.35). Post hoc 
analyses suggested that the treatment may be most effective in women (VAS 
-16.8mm, p=0.008) and those with milder radiographic osteoarthritis (VAS -
16.1mm, p=0.009).  Local rash was more common amongst participants 
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receiving 4Jointz (21% v 1.6%, IRR 13.2, p=0.013), but only 26% (n=4) of 
participants with rashes discontinued treatment. There were no changes in 
systemic blood results and no differences in adverse events between 
patients receiving 4Jointz and placebo. 
Conclusions:  Topical treatment using 4Jointz reduced pain and increased 
muscle strength but had no effect on inflammation or cartilage breakdown 
over twelve weeks of treatment.  
 
  





Knee osteoarthritis (OA) is common and is associated with pain and ongoing 
disability. Management of osteoarthritis involves symptom control, usually 
non-steroidal anti-inflammatory medications (NSAIDs) or analgesic 
medication in early arthritis, and then joint replacement when the disease 
progresses to more severe stages.  
The controversy surrounding the use of the COX-2 inhibitor class of NSAIDs 
and heightened cardiovascular risk (Bombardier, 2000; Bresalier, 2005; 
Caughey, 2011; Solomon, 2005), highlights the importance of finding safer 
treatment options to minimise adverse side effects. Natural agents such as 
capsaicin (Katz and Shah, 2009) and vitamins (McAlindon, 1996) have 
demonstrated improved overall patient outcomes, and may play a role in 
treatment of OA even if they are only moderately effective.   
Comfrey (Symphytum officinale) is traditionally used for the treatment of bone 
fractures, sprains and wounds (Bleakley, 2008), as it demonstrates anti-
inflammatory and analgesic properties. A topical comfrey application (vs. 
placebo) on acute ankle sprains in 142 participants has been shown to 
decrease pain and swelling and improve mobility (Koll, 2004). In other 
studies on ankle distortions sole comfrey therapy was reported as being as 
effective and possibly superior to diclofenac gel (D'Anchise, 2007; Predel, 
2005). Comfrey has also been used in an earlier study to specifically treat OA 
with two thirds of recipients reducing or discontinuing their NSAID 
treatment (Koll and Klingenburg, 2002).  Moreover, in a study involving 220 
patients diagnosed with OA, those utilising topical Comfrey therapy reported 
a marked reduction in VAS pain scores (Grube, 2007).  
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Persons with OA have been reported to have high levels of free radicals and 
reduced levels of antioxidants within the joint fluid (Regan, 2008). The 
presence of oxygen free radicals in the synovial joint fluid of persons with 
osteoarthritis act as chemical messengers responsible for the pathogenesis 
of osteoarthritis (Yudoh, 2005). Antioxidants (such as tannic acid) are 
protective against the extracellular matrix cartilage degradation that radicals 
yield (Cho, 2009) and can also augment glycosaminoglycan binding to 
collagen. This ultimately contributes to the structural reinforcement of 
synovial articulating surfaces (Levanon and Stein, 1995). Preparations of 
tannic acid have been found to be superior to placebo in reducing pain and 
stiffness and improving physical function in primary OA (McAlindon, 1996). 
Therefore, a number of complementary medicinal agents may be effective in 
reducing pain and inflammation.  A pilot study of treatment using two different 
concentrations of comfrey vs placebo (Smith and Jacobson, 2011) showed 
that the comfrey / tannic acid mixtures were both superior to placebo in 
reducing WOMAC pain and stiffness scores. In a previous study, (Grube, 
2007) researchers compared a comfrey root extract with placebo for painful 
knee OA and observed a 40mm difference in pain VAS score, and 46mm 
reduction in WOMAC score between comfrey and placebo after three weeks.  
However, this trial has substantial methodological weaknesses which reduce 
confidence in its’ findings.  These include: short duration of follow up; 
absence of baseline patient summary data; lack of information on how 
participants were randomised, how blinding was achieved for patients or 
assessors, or methods used to confirm knee OA. 
This study compared the effect of thrice daily topical 4Jointz utilizing Acteev 
technology (a novel and patented combination of a standardized comfrey 
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extract and a pharmaceutical grade tannic acid, 3.5 g/day), or placebo on 
osteoarthritic knee pain, muscle strength, and markers of inflammation and 
cartilage breakdown over twelve weeks in participants aged >50 with 
clinically diagnosed OA and a pain intensity score >40mm on a visual 
analogue scale (VAS).   
  





A3.2.1 Trial design 
This study was a two centre double blind parallel-group placebo controlled 
randomised trial of topical treatment 4Jointz vs placebo with a 1:1 allocation 
ratio. 
A3.2.2 Settings and locations 
Participants were recruited from September 2010 to May 2011 through 
advertising in local print media in Hobart, Tasmania and Sydney, New South 
Wales in Australia.  Participants attended clinics at either the Menzies 
Research Institute Tasmania in Hobart, or the Royal North Shore Hospital in 
Sydney. 
A3.2.1.1 Inclusion and exclusion criteria 
Participants were aged >50 years, with clinically diagnosed knee OA using 
ACR criteria (Altman, 1995), and had knee pain on most days of >40mm on a 
100mm visual analog scale (VAS) in their worst knee.  Participants were 
excluded if they had knee X-rays with joint space narrowing (JSN) of Grade 3 
using the Osteoarthritis Research Society International (OARSI) 
atlas (Altman, 1986), read by chief investigators (GJ and LM) on diagnostic 
radiographs; had other forms of arthritis (including hip osteoarthritis); had 
significant knee injury in the last six months; or were unable to provide 
informed consent.  Participants who were otherwise eligible and those who 
had Grade 3 JSN in their worst knee were able to enter the study if JSN was 
<3 in the other knee. 
A3.2.3 Participants 
Participants were screened over the telephone.  If they met the inclusion 
criteria and did not meet the exclusion criteria, they were invited to attend a 
Appendix 3:  4Jointz report 
 
Page 246 
study centre for screening.  Screening and examination was undertaken by a 
rheumatologist (GJ, LM) and a nurse (MC, MG, TF).  Participants supplied a 
blood specimen for serum chemistry, renal function and inflammatory 
markers; a urine sample for cartilage metabolites; and had a semi-flexed 
knee X-ray.  Use of other medication (including pain medicines) was allowed 
but kept constant through the trial period where possible.  All participants 
provided written consent.  The study was approved by the Human Research 
Ethics Committee (Tasmania) Network and the Northern Sydney Local 
Health District Human Research Ethics Committee. 
A3.2.4 Interventions 
Participants received either 4Jointz cream (active) or identical inert placebo 
cream.  The active treatment was a combination of a standardized comfrey 
extract (200 mg/g) and pharmaceutical grade tannic acid (100 mg/g) plus 
other ingredients including aloe vera (300 mg/g), eucalyptus oil (40 mg/g), 
and frankincense oil (1.0 mg/g). 
Participants were instructed to apply enough cream to coat the knee with a 
thin coating which was then massaged in using gentle circular motions for 3–
5 minutes, three times daily. Therefore the daily dose was approximately 3.5 
g/day. Participants were supplied with one 100g tube of cream at each visit.  
Study medication was stored in a locked cupboard prior to dispensing, and 
dispensed when patients successfully completed the screening visit(s).  
Treatment continued for twelve weeks, where medication use was 
discontinued while maintaining the blind.  Participants were re-assessed at 
16 weeks. 




Primary hypotheses were that 4Jointz was superior to placebo at twelve 
weeks for change in: knee pain (using the pain intensity VAS and the pain 
scale from the Knee Injury and Osteoarthritis Outcome Score Questionnaire 
(KOOS)); markers of inflammation (IL-6), and cartilage breakdown (CTX-2). 
Secondary hypotheses were that 4Jointz was superior to placebo for change 
in: pain between baseline and four and eight weeks of treatment; response 
using the OARSI response criteria (Pham, 2004), lower limb muscle strength 
and use of paracetamol between baseline and four, eight and twelve weeks.   
A3.2.6 Outcome measures 
A3.2.6.1 Pain and function 
Knee pain intensity was measured using a 100mm visual analogue scale on 
four occasions (baseline, four, eight, twelve and sixteen weeks).  Participants 
were asked “on this line, where would you rate your pain today?”. 
Knee pain and symptoms were also assessed using the KOOS questionnaire 
on all five occasions (Roos, 1998). These two subscales have nine (pain) 
and seven (symptoms) questions, each with five response levels scored from 
0–4. Subscales were transformed according to instructions in the original 
manuscript (Roos, 1998). The transformed scale had possible values from 0–
100 with zero representing extreme knee pain or symptoms and 100 
representing no knee pain or symptoms. Baseline questionnaires were 
completed in the clinic.  Subsequent questionnaires were completed by mail.   
A3.2.6.2 Inflammation and cartilage breakdown 
Urine and blood samples were stored at -80°C.  Baseline and twelve week 
urine samples were assayed for the cartilage breakdown marker CTX-II in 
one batch in duplicate using a Human CTX-2 ELISA kit (Cusabio Biotech Co, 
Hubei Province, China), and following the manufacturers’ instructions.  Urine 
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was diluted by half, and absorbance was read at 450nm with reference 
wavelength at 570nm.  Samples with <1 ng/mL were deemed out of range 
and analysed with a value of zero. 
Baseline and twelve week blood samples were assayed for the inflammatory 
marker IL-6 in one batch in duplicate using a Human IL-6 ELISA MAX Deluxe 
SET kit (Biolegend, California, USA), and following the manufacturers’ 
instructions.  Sera was used neat, and absorbance was read at 450nm with 
reference wavelength at 570nm.  Samples with <1 pg/mL were deemed out 
of range and analysed with a value of zero. 
A standard curve was run on each plate, in duplicate (R2 >0.997).  
Absorbance was read using SoftMax Pro software, which calculated the 
standard curves and concentrations for each unknown on a plate by plate 
basis.  
A3.2.6.3 OMERACT-OARSI response criteria 
Response to 4Jointz was assessed using a modified version of the 
OMERACT-OARSI set of response criteria (Pham, 2004).  Participants were 
classed as responding if they had high improvement in pain (using the VAS) 
or function (using KOOS function scale) of ≥50% and absolute change ≥20; 
or if they had improvement in both pain and function of ≥20% or ≥10.  Criteria 
for change in participants’ global assessment were not included. 
A3.2.6.4 Paracetamol usage 
Paracetamol usage was recorded at baseline (along with other medication) 
and at each subsequent visit.  For participants who did not use paracetamol 
daily, the dose taken was averaged to a daily dose over a 28 day month. 
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A3.2.6.5 Muscle strength 
Leg strength was measured to the nearest kilogram in both legs 
simultaneously, using a dynamometer (TTM Muscular Meter, Tokyo, Japan) 
as previously described (Scott, 2009).  This tests isometric strength, 
predominantly of the quadriceps and hip extensors.   
A3.2.6.6 Safety 
Adverse events were defined as any untoward event occurring during the trial 
regardless of whether it was considered medication-related.  Serious adverse 
events were defined as unplanned hospital admissions, new cancer 
diagnoses or death during the 16 weeks of the study.  Blood tests were 
performed at baseline and 12 weeks to assess safety, and included general 
biochemistry, red and white cell parameters and platelet counts. 
A3.2.7 Sample size 
Sample size for pain intensity using VAS was based on demonstrating a 
10mm greater reduction compared to placebo with a SD of 20mm (Langford, 
2006; Raynauld, 2004).  A change of 10mm reduction on the VAS (compared 
to placebo) required 62 participants per group with =0.05 and  =0.20.  
Therefore, we aimed to enrol 70 participants in each group to allow for 
dropouts. 
A3.2.8 Randomisation and sequence generation 
Participants were randomly allocated to one of two treatment arms (4Jointz 
or placebo) using computer generated block randomisation in blocks of four.  
The random allocation sequence was automatically generated, and a security 
protected central automated allocation procedure was used to allocate 
participants to treatment arm 1 or 2.  This was then used by one author (LL, 
who had no contact with participants) to dispense the allocated medication 
for the Hobart participants.  Research nurses enrolled participants in the trial, 
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and then gave tubes of cream to each individual patient.  The procedure for 
Sydney patients was the same except that the pharmacy at the Royal North 
Shore Hospital dispensed allocated medication to Sydney participants.  The 
active treatment and placebo product were visually and aromatically identical.  
Participants and staff involved in patient care remained blinded to treatment 
allocation throughout the trial. 
A3.2.9 Statistical methods 
We used Stata 12.0 (StataCorp LP) for statistical analyses.  Statistical 
significance was set as a p value ≤0.05 (two-tailed).  We used a modified 
intent to treat (ITT) approach for data analysis, where all patients who were 
randomised to receive treatment were included in the analysis.  Change in 
outcomes were assessed using the difference between the factor at baseline 
and follow up and assessed using linear regression.  Normality checks were 
done using Stata’s pnorm and qnorm functions.  Change in CTX-2 and 
change in IL-6 both had one highly influential outlier (>99th percentile) which 
was omitted from analysis in order to satisfy requirements of normality for 
linear regression.  Poisson regression was used to compare numbers of 
adverse events, with data checked for overdispersion.  Change in binary 
outcomes were assessed using logistic regression for panel data (xmelogit) 
and clustering on ID to account for correlated outcomes within an individual.   
Post-hoc analyses on the change in outcomes by sex, OARSI grade and BMI 
were also performed, using linear regression.  Sensitivity analyses were 
performed on estimates of the effect of treatment between baseline and 
twelve week, adjusting for covariates where there was a statistically or 
clinically significant difference at baseline (OARSI grade, use of paracetamol, 
use of glucosamine).  





A3.3.1 Study participants 
Figure A3. shows that a total of 167 participants attended screening for the 
study.  34 participants were excluded after initial screening.  Most of these 
(n=30) had knee OA which was too severe (Grade 3 JSN).  The remaining 
133 participants were randomised to receive either 4Jointz or placebo.  After 
twelve weeks of follow-up (the time at which the main outcomes were 
assessed), 81% of the cohort had been retained, 88% in the placebo group 
and fewer patients (75%) in the intervention group (p=0.03).  
  





Figure A3.1: Study flow chart 
 
Table A3.1 shows that participants were predominantly middle aged, 
overweight women.  One in eight had experienced previous surgery, and the 
average pain intensity indicated that these participants were in moderate to 
 
Assessed for eligibility (n=167) 
Excluded (n=34) 
 Met exclusion criteria (n=32): 
 VAS<40mm (n=1) 
 JSN Grade 3 (n=30) 
 Other form of arthritis (n=1) 
 Declined to participate (n=1) 
 Other Reasons (n=1): 
 Referred pain from hip (n=1) 
Lost to follow-up (n=3) 
 Refused to continue (n=3) 
Lost to follow-up (n=4) 
 Refused to continue (n=4) 
Allocated to PLACEBO (n=64) 
 Received allocated intervention (n=64) 
Lost to follow-up (n=4) 
 Refused to continue (n=3)  
 Non-elective admission for cardiac 
surgery (n=1) 
Allocated to 4JOINTZ (n=69) 
 Received allocated intervention (n=69) 
Lost to follow-up (n=9) 
 Refused to continue (n=5) 
 Rash (n=1) 
 Increased knee pain (n=1) 
 Other (n=2) 
Allocation 
Follow-Up: 8 weeks 
Follow-Up: 4 weeks 
Randomized (n=133) 
Enrollment 
Lost to follow-up (n=1) 
 Increased pain (n=1) 
Lost to follow-up (n=4) 
 Refused to continue (n=1)  
 Rash (n=2) 
 Other (n=1) 
Follow-Up: 12 weeks 
Treatment ceases 
Lost to follow-up (n=2) 
 Refused to continue (n=2) 
Lost to follow-up (n=5) 
 Refused to continue (n=3)  
 Rash (n=1) 
 Unable to contact (n=1) 
Follow-Up: 16 weeks 
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severe pain on most days despite being on up to three different pain 
medications.   
The participants receiving 4Jointz and placebo were well matched.  The 
groups were different in their use of glucosamine (p=0.04) and number of 
pain medicines used (p=0.049), which was predominantly differences in use 
of paracetamol and glucosamine.    
Table A3.1:  Baseline characteristics of study patients 
 4Jointz Placebo 
 n=64 n=69 
 mean (sd) mean (sd) 
Age 64.3 (9.8) 65.5 (8.3) 
Sex (% male) 45 36 
Weight 83.3 (15.9) 81.6 (16.6) 
BMI 29.7 (4.9) 29.9 (5.1) 
Medication use   
Paracetamol (%) 30 41 
Average paracetamol dose (mg) 1710 (1374.9) 1475 (1165.7) 
Fish oil (%) 30 34 
Glucosamine (%) 22 38 
COX-2 inhibitors (%) 14 16 
Radiographic OA (n,%)*   
   Grade 0 12 (17) 18 (28) 
   Grade 1 24 (35) 13 (20) 
   Grade 2 22 (32) 21 (33) 
   Grade 3 0 0 
Number of pain medicines (n, %)   
   0 31 (45) 16 (25) 
   1 18 (26) 17 (27) 
   2 7 (10) 16 (25) 
   3 13 (19) 15 (23) 
Previous knee surgery, self-reported (%) 10 14 
Pain intensity (VAS score) 52.7 (15.7) 53.8 (14.5) 
Pain intensity (KOOS) 57.0 (12.7) 56.2 (15.5) 
Symptoms score (KOOS) 59.6 (14.9) 58.6 (16) 
IL-6 (pg/mL) 5.7 (7.2) 6.4 (13.9) 
CTX-2 (ng/mL) 20.8 (48.4) 21.5 (38.5) 
*Radiographic OA assessed using OARSI criteria 
  





Data on the main outcomes are shown in Table A3.2.  Data was analysed 
using all available data points.  
Primary hypotheses 
For the primary hypotheses of changes between baseline and twelve weeks, 
the data shows that the treated group had an significantly greater reduction in 
knee pain on the VAS scale averaging 9.9mm (p=0.034) compared to 
placebo. It also showed a significant improvement, 5.7 points on the KOOS 
pain scale (p=0.047).  Neither change in IL-6 (-1.6, 95% CI -4.0 to 0.8; p=0.2) 
nor change in cartilage breakdown (2.8, 95% CI -10.6 to 16.1; p=0.68) were 
significantly different between baseline and twelve weeks. 
Secondary outcomes 
The change in pain recorded using the KOOS pain scale was significantly 
different by eight weeks, with patients receiving 4Jointz experiencing less 
pain (6.1, p=0.025).   
Participants receiving 4Jointz also had greater leg strength (2.9 kg, p=0.02) 
after twelve weeks of treatment, this result remained statistically significant 
after adjustment for baseline differences.  
  
 
Table A3.2: Effect of treatment with 4Jointz: study outcomes after four, eight and twelve weeks of treatment, using change models 
 4 weeks  8 weeks  12 weeks  16 weeks  
 Beta (95% CI) p Beta (95% CI) p Beta (95% CI) p Beta (95% CI) p 
 n=124  n=112  n=106  n=101  
Pain (VAS) -3.0 (-10.4 to 4.4) 0.42 -5.7 (-13.8 to 2.3) 0.16 -9.9 (-19.1 to -0.8) 0.034 -2.4 (-11.6 to 6.7) 0.60 
Pain (KOOS) 1.3 (-3.3 to 5.9) 0.58 6.1 (0.8 to 11.4) 0.025 5.7 (0.1 to 11.3) 0.047 0.03 (-7 to 7.1) 0.99 
Symptoms 1.7 (-2.6 to 6.0) 0.45 -0.2 (-5.3 to 4.9) 0.94 4.7 (-1.3 to 10.7) 0.12 -2.5 (-8.6 to 3.6) 0.43 
Leg strength (kg) -0.02 (-2.4 to 2.4) 0.99 1.9 (-0.6 to 4.5) 0.13 2.9 (0.5 to 5.3) 0.02 1.5 (-1.3 to 4.3) 0.30 
IL6 -  -  -1.6 (-4.0 to 0.8) 0.20 -  
CTX-2 -  -  2.8 (-10.6 to 16.1) 0.68 -  
OMERACT-OARSI response 
criteria¥ 1.2 (0.7 to 2.1) 0.56 1.4 (0.82 to 2.4) 0.22 1.3 (0.8 to 2.2) 0.34 1.1 (0.7 to 2) 0.63 
Paracetamol use (yes / no) ‡ 1.0 (0.6 to 1.7) 0.85 1.0 (0.8 to 1.4) 0.82 1.0 (0.8 to 1.2) 0.8 1.0 (0.8 to 1.1) 0.67 
Paracetamol dose (in those 
using at baseline) 
-70.7  
(-759.9 to 618.6) 0.84 
-247.6  
(-925.6 to 430.5) 0.46 
-404.2  
(-1268.8 to 460.4) 0.35 
-734.9  
(-1615.7 to 145.8) 0.098 
The statistics presented are the change in the outcome between baseline and the time point of interest except the response criteria. 
The number presented is the beta coefficient (and 95% CI) for the additional effect of treatment over that of placebo except where ‡odds ratios or  
¥Poisson regression is used, where indicated. 












Table A3.3:  Offset effect- change in study outcomes when treatment ceases (between 12 and 16 weeks of observation) 
 




Pain (VAS) 9.2 (0.4 to 17.9) 0.04 
Pain (KOOS) -6.8 (-13 to -0.5) 0.034 
Symptoms -8.5 (-14.1 to -2.8) 0.004 
Leg strength (kg) -2.5 (-4.9 to -0.1) 0.04 
OMERACT-OARSI response criteria¥ 1.1 (0.7 to 2.0) 0.63 
Paracetamol use  (yes / no) ‡ 0.2 (0.02 to 1.5) 0.11 
Paracetamol dose (in those using at baseline) -308.9 (-802.8 to 185) 0.21 
Statistics presented are the change in the outcome between baseline and the time point of interest except the response criteria. 
The number presented is the beta coefficient (and 95% CI) for the additional effect of treatment over that of placebo except 
where ‡odds ratios or ¥ Poisson regression is used, where indicated.  















A3.3.3 Individual outcomes 
A3.3.3.1 Pain intensity (using visual analog scores) 
Figure A3.2 shows that pain intensity decreased in both groups at the 
beginning of the trial period and plateaus in the placebo group after eight 
weeks of treatment.  By twelve weeks of treatment, difference in the change 
scores between groups were statistically significant (-9.9 mm, 95% CI -19.1 
to -0.8; p= 0.034), see Table A3..  This remained significant after adjustment 
for differences in the group at baseline (baseline paracetamol and 
glucosamine use, and OARSI grade).  After the treatment was discontinued, 
the differences between the groups rapidly reduced (9.2mm (95% CI 0.4 to 
17.9); p=0.04 (Table A3.3). 
 
Figure A3.2: Pain intensity (using the visual analog scores) over sixteen 
weeks of treatment, by treatment received  




A3.3.3.2 KOOS results 
Figure A3.3 shows that pain intensity (as measured using the KOOS 
questionnaire) reduced in both groups at the beginning of the trial period 
(note:  “no pain” is zero on the KOOS scale, not 100) and plateaus in the 
placebo group after four weeks of treatment.  By eight weeks of treatment, 
the difference in the change scores between groups were statistically 
significant (6.1, 95% CI 0.8 to 11.4; p= 0.025), this difference remained 
significant at twelve weeks (5.7, 95% CI 0.1 to 11.3; p= 0.047), see Table 
A3..  After adjustment for baseline paracetamol and glucosamine use, and 
OARSI grade, the effect of treatment was no longer significant, but the 
magnitude of the effect was similar (5.2, p=0.12) and none of the covariates 
were statistically significant.  After the treatment was discontinued, the 
differences between the groups rapidly decreased (-6.8, 95% CI -13 to -0.5; 
p=0.034, Table A3.3). 
For symptoms, differences in change scores between the group receiving 
placebo and 4Jointz were not statistically significant at any time point, except 
between twelve and sixteen weeks when the treatment was discontinued (-
8.5, -14.1 to -2.8; 0.004). 
  





Figure A3.3: Pain intensity (as measured using the KOOS questionnaire) over 
sixteen weeks of treatment, by treatment received 
 
Figure A3.4: Symptom scale, as measured using the KOOS questionnaire, 










































A3.3.3.3 Cartilage breakdown  
Changes in the cartilage breakdown marker CTX-2 were not significant 
between baseline and twelve weeks (See Table A3.2, Figure A3.5), and 
remained non-significant after adjusting for baseline differences.  
 
Figure A3.5: CTX-2, by treatment received 
  




A3.3.3.4 Systemic inflammation 
Changes in the measure of systemic inflammation (IL-6) were not significant 
between baseline and twelve weeks (See Table A3.2, Figure A3.6), and 
remained non-significant after adjusting for baseline differences. 
   
Figure A3.6: IL6, by treatment received 
  




A3.3.3.5 Paracetamol use 
Usage of paracetamol was assessed in two ways, firstly whether participants 
were using paracetamol or not (prevalence of paracetamol use), and daily 
dose of paracetamol used amongst persons reporting paracetamol use at 
baseline. 
Treatment with 4Jointz did not change prevalence of paracetamol use (using 
compared to not using) over the duration of the trial, nor did it change when 
treatment ceased after week 12, after adjustment for baseline paracetamol 
use (p=0.11, Table A3.3). More participants in the placebo group used 
paracetamol at baseline than persons receiving 4Jointz (see Table A3.2, 
Figure A3.7), but this difference also did not reach statistical significance 
(p=0.09).   
 
Figure A3.7:  Proportion of participants using paracetamol over sixteen weeks 
of treatment, by treatment received 
  




Figure A3.8 shows that among persons using paracetamol at baseline (n=47) 
treatment with 4Jointz decreased the daily dose of paracetamol taken over 
the duration of the trial (weeks 1-12) by 404mg but this did not reach 
statistical significance (p=0.35).  Similarly, daily dose of paracetamol was not 
different between groups when treatment ceased (week 12-16, see Table 
A3.3).  Variation within the groups (as seen with the 95% confidence intervals 
of the estimates) was large compared to the observed effect sizes. 
 
Figure A3.8: Daily dose of paracetamol (mg) over sixteen weeks, in 
participants using paracetamol at baseline, by treatment received 
  




A3.3.3.6 Leg strength 
Figure A3.9 shows that the groups receiving placebo and 4Jointz began to 
diverge in their leg strength measures by eight weeks, and by twelve weeks 
the differences in change scores between the two groups had reached 
statistical significance (2.9, 95% CI 0.5 to 5.3; p=0.02), see Table A3.2.  Leg 
strength remained significant after adjustment for baseline differences and 
reduced when treatment ceased (-2.5kg, p=0.04).  
   
Figure A3.9: Leg strength over sixteen weeks of treatment, by treatment 
received 
  




A3.3.3.7 OMERACT – OARSI response criteria 
Figure A3.10 shows the response to treatment using a modified form of the 
OMERACT-OARSI response criteria.  Response to treatment was not 
different between participants receiving 4Jointz and placebo, at any time 
point.  
 
Figure A3.10: Response to treatment using a modified version of the 
OMERACT – OARSI response criteria, by treatment received 
  




A3.3.4 Post-hoc analyses 
Additional analyses were conducted on the pain measures.  These were 
analyses decided after the trial concluded, and are therefore of a hypothesis-
generating rather than a hypothesis-answering nature. 
A3.3.4.1 Gender 
We investigated the effect of treatment with 4Jointz (vs placebo) on pain 
intensity on men compared to women; persons with different grades of 
radiographic knee OA, initial pain score (above / below a VAS of 50), and 
BMI (above / below a BMI of 25). 
Women responded better to treatment than men, using both the VAS pain 
intensity score and the KOOS pain scale (see Table A3.4, Figure A3.11 and 
Figure A3.12). 
Table A3.4: Change in pain scores between baseline and twelve weeks, by 
gender and treatment group 
Change 
in  n Placebo n 4Jointz Diff p 
VAS 
score  
Females 36 -12.9 (-21.7 to -4.1) 24 -29.7 (-37.1 to -22.2) -16.8 0.008 




Females 35 1.9 (-2.8 to 6.6) 23 10.6 (5.2 to 16.0) 8.7 0.018 
Males 19 11.0 (6 to 16) 26 10.9 (3.8 to 18.1) -0.1 0.99 
 
  






Figure A3.11a and b:  Effect of treatment on pain intensity in women and men, 
by treatment received 
  






Figure A3.12 a and b: Effect of treatment on KOOS pain score in women and 
men, by treatment received 
  




A3.3.4.2 OARSI grade and BMI 
The effect of treatment by radiographic staging of OA was also investigated, 
using OARSI grade, and by body mass index (below / above a BMI of 25). 
After twelve weeks of treatment, 4Jointz was effective in treating persons 
with OARSI grades of 0 and 1 but not those with OARSI grade 2 (see Figure 
A3.13).   
Treatment appeared more effective in participants who were overweight or 
obese, but this did not reach statistical significance.  The effect size was 
similar in participants with BMI below 25 as above 25 so this may merely 
reflect the smaller number of persons in the healthy weight range in the 
sample. 
Table A3.5: Change in VAS score between baseline and twelve weeks, by 
OARSI grade and body mass index. 
 n PLACEBO n 4Jointz Diff p 
OARSI grade       
0 or 1 29 -9.9 (-20.3 to 0.5) 26 -26.0 (-31.6 to -20.4) -16.1 0.009 
2 17 -22.3 (-33.7 to -10.9) 16 -29.6 (-42 to -17.3) -7.3 0.36 
BMI<25 9 -20.6 (-39.2 to -1.9) 7 -31.1 (-58.6 to -3.7) -10.6 0.45 
BMI 25+ 47 -14.6 (-22.2 to -7.0) 41 -24.4 (-30.9 to -17.9) -9.8 0.06 
 
  






Figure A3.13a and b: Effect of treatment on pain intensity in persons by 








A3.3.5 Adverse events 
Adverse events were common in this cohort, with 61% (n=62) of the placebo 
group and 72% (n=66) of the 4Jointz group experiencing at least one 
adverse event.  Differences in prevalence and actual number of events were 
not significant (Table A3.6).   
One aspect of the adverse events was significantly different between persons 
receiving 4Jointz and placebo.  Localised skin irritation at the site of 
application (“rash”) was significantly higher in patients receiving 4Jointz (risk 
ratio 13.2, p=0.013).  Participants experiencing localised irritations were 
advised to cease using the treatment, then rechallenge with cream after a 
few weeks.  Treatment ceased if the rash recurred.  Rashes were severe 
enough to discontinue the study drug in four participants (26% of those with 
rash) (Table A3.6).  One participant had a serious adverse event, which was 
a non-elective hospital admission where they received a cardiac stent.  We 
think this is unlikely to be causally related to the use of 4Jointz.  Over 40% of 
participants had at least one change in their blood results between baseline 
and twelve weeks, but differences between participants receiving 4Jointz and 
placebo were not significant.  
Overall, these results show that 4Jointz is safe and effective amongst 50-80 
year old adults with clinical diagnosed knee osteoarthritis.  The only adverse 
event experienced more commonly in persons receiving 4Jointz compared 
those receiving placebo for knee pain is a localised skin irritation, which 
recurred in a minority after a break in treatment.   
  




Table A3.6: Prevalence and number of adverse events, by treatment received 
 Placebo 4Jointz p 
 n=62 n=67  
Adverse events    
Prevalence of at least one 
adverse event (n, %)  38 (61) 48 (72) 0.47 
Number of adverse events  67 78 0.85 
Prevalence of (n, %)    
Rash 1 (1.6) 14 (21.2) 0.013 
Upper respiratory tract infection 11 (17.7) 10 (15.2) 0.69 
GI Upset 4 (6.5) 2 (3) 0.37 
Headache 3 (4.8) 6 (9.1) 0.38 
Increased knee pain 3 (4.8) 2 (3) 0.60 
Knee swelling 1 (1.6) 1 (1.5) 0.96 
Abnormal blood results 24 (41) 29 (44) 0.82 
Elective hospital admissions 3 (4.8) 1 (1.5) 0.31 
Serious adverse events    
Number of non-elective hospital 
admissions 0 1  
Cancer 0 0  









This study has demonstrated that 4Jointz is a safe and effective topical 
treatment for moderate to severe knee OA in participants aged 50-80 years.  
4Jointz was effective in reducing pain at twelve weeks using both the VAS 
and the KOOS scales, and by 8 weeks using the KOOS scale.  4Jointz also 
increased quadriceps strength by an average of 3 kg after 12 weeks. It had 
no effect on systemic inflammation or cartilage breakdown over twelve weeks 
of treatment.   
This clinical trial has the longest reported duration of use of comfrey for 
osteoarthritic knee pain, with previous trials being of three (Grube, 2007) or 
six weeks duration  (Smith and Jacobson, 2011).  Patients had the largest 
responses to treatment at the last occasion during treatment in this study (12 
weeks) and therefore if treatment continues past this time, patients may 
continue to benefit.  
Treatment was discontinued after twelve weeks and pain, other symptoms 
and leg strength significantly worsened.  This suggests that there is a rapid 
offset, and continuing treatment longer than twelve weeks may result in 
continuing benefit. 
The results from this study are consistent with those of two other 
trials (Grube, 2007; Smith and Jacobson, 2011), in that all support a role for 
comfrey as a topical treatment for knee pain and OA.  However, it is not 
possible to directly compare results between all studies because the patient 
populations are different, and the studies use different outcome measures, 
requiring in-depth analysis of the results to make any reasonable 
comparisons. 
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Grube et al (2007) included patients with long term knee pain (not clinically 
diagnosed OA) and with pain scores (on VAS) as low as 23mm and patients 
discontinued taking other medications suggesting that participants may not 
have knee OA, or are earlier in the disease course. The larger effect 
observed in this study is consistent with our results in early OA.  Omitting 
participants taking analgesics or anti-inflammatory medications would have 
ruled out nearly 60% participants in the 4Jointz study and thus these results 
should be seen as an additional benefit of 4Jointz rather than the only 
benefit.  Grube et al (2007) also observed a much greater reduction in pain 
with the use of comfrey than this study at a comparable time point.  This may 
be due to the use of an aggregate of the WOMAC subscales “pain at rest” 
and “pain on movement”.  This is misleading as adding these values is not a 
representation of either pain scale, does not represent the actual pain levels 
of the patients and artefactually doubles the apparent magnitude of benefit. 
Since post hoc analyses suggested that treatment may be most effective in 
women and those with milder radiographic osteoarthritis, future research 
should consider studies specifically in these populations. 
We observed clinically important changes in self–rated outcomes in the 
group receiving placebo as well as those receiving 4Jointz.  These were most 
evident with pain but we also observed them in the KOOS symptom score.  
This is consistent with a meta-analysis of the placebo effect in clinical trials of 
treatment for OA (Zhang, 2008), in which effect sizes of 0.26 were reported 
for placebo in trials of herbal treatments.  This highlights the importance of 
using randomised controlled trials to assess the efficacy of all pharmaceutical 
treatments. 
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The side effect profile observed was similar to that reported in a pilot study of 
4Jointz (Smith and Jacobson; Grube, 2007).  Overall 4Jointz appears safe 
and well tolerated.  Most importantly, the renal toxicity associated with 
pyrrolizidine-type alkaloids, associated with oral use of comfrey (Stickel and 
Seitz, 2000) appears absent in topical use, as expected. The skin irritation 
appears causally related to the use of 4Jointz as it reversed on cessation of 
treatment, and only reappeared in around one fifth of those with rash. 
We supplied participants with one tube of cream per month.  We have 
observed clinically significant changes with one tube of cream per month or 
about 3.5g/day.  Since only one dose of 4Jointz was used in this study we 
cannot compare with other concentrations.  However, Smith et al compared 
formulations of, 10% and 20% comfrey extract and pseudoplacebo, and 
whilst both were superior to placebo, the treatment arms were not 
significantly different from each other (Smith and Jacobson, 2011). 
Strengths of this study include the comparatively long duration of treatment, 
the defined study population and standardised meaningful outcome 
measures.  The major limitation of this study is the difference in dropout rates 
between the groups receiving placebo and 4Jointz, with more patients 
ceasing treatment in the 4Jointz group.  This included but was not limited to 
patients who experienced rash and were advised to cease treatment. 
Conclusions  
Topical treatment using 4Jointz is a safe and effective treatment for the 
symptoms of OA. In particular, it reduces pain and increases muscle 
strength, but has no effect on systemic inflammation or cartilage breakdown 
over twelve weeks of treatment.  
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